Original Article
gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma
N Engl J Med 2011; 364:2119-2127June 2, 2011DOI: 10.1056/NEJMoa1012863
- Abstract
Background
Stimulating an immune response against cancer with the use of vaccines remains a challenge. We hypothesized that combining a melanoma vaccine with interleukin-2, an immune activating agent, could improve outcomes. In a previous phase 2 study, patients with metastatic melanoma receiving high-dose interleukin-2 plus the gp100:209-217(210M) peptide vaccine had a higher rate of response than the rate that is expected among patients who are treated with interleukin-2 alone.
Methods
We conducted a randomized, phase 3 trial involving 185 patients at 21 centers. Eligibility criteria included stage IV or locally advanced stage III cutaneous melanoma, expression of HLA*A0201, an absence of brain metastases, and suitability for high-dose interleukin-2 therapy. Patients were randomly assigned to receive interleukin-2 alone (720,000 IU per kilogram of body weight per dose) or gp100:209-217(210M) plus incomplete Freund's adjuvant (Montanide ISA-51) once per cycle, followed by interleukin-2. The primary end point was clinical response. Secondary end points included toxic effects and progression-free survival.
Results
The treatment groups were well balanced with respect to baseline characteristics and received a similar amount of interleukin-2 per cycle. The toxic effects were consistent with those expected with interleukin-2 therapy. The vaccine–interleukin-2 group, as compared with the interleukin-2–only group, had a significant improvement in centrally verified overall clinical response (16% vs. 6%, P=0.03), as well as longer progression-free survival (2.2 months; 95% confidence interval [CI], 1.7 to 3.9 vs. 1.6 months; 95% CI, 1.5 to 1.8; P=0.008). The median overall survival was also longer in the vaccine–interleukin-2 group than in the interleukin-2–only group (17.8 months; 95% CI, 11.9 to 25.8 vs. 11.1 months; 95% CI, 8.7 to 16.3; P=0.06).
Conclusions
In patients with advanced melanoma, the response rate was higher and progression-free survival longer with vaccine and interleukin-2 than with interleukin-2 alone. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT00019682.)
Media in This Article
Figure 1Progression-free and Overall Survival.Progression-free survival (Panel A) was longer among patients receiving vaccine and interleukin-2 than among those receiving interleukin-2 alone. The median progression-free survival among patients who received the vaccine was 2.2 months (95% confidence interval [CI], 1.7 to 3.9), as compared with 1.6 months (95% CI, 1.5 to 1.8) among patients who did not receive the vaccine. There was a trend toward longer overall survival (Panel B) among patients receiving vaccine and interleukin-2 than among those receiving interleukin-2 alone. The median survival among patients who received the vaccine was 17.8 months (95% CI, 11.9 to 25.8), as compared with 11.1 months (95% CI, 8.7 to 16.3) among patients who did not receive the vaccine.
Table 1Baseline Characteristics of the Patients.
Article Activity
- Article
Although it is clear that vaccines are important in the prevention of infectious diseases, their benefits with respect to metastatic cancer have been less clear. One of the first studies to show improved survival with vaccines among patients with metastatic cancer was reported recently in a study involving men who received sipuleucel-T vaccine for the treatment of metastatic castration-resistant prostate cancer.1 We hypothesized that the effectiveness of cancer vaccines could be improved by the simultaneous administration of specific antigens and cytokines to drive the immune response.2
Melanoma, a tumor that may be innately immunogenic in humans, is an important model for the study of tumor immunity. Although early stages of melanoma can be cured by means of surgery, the prognosis for patients with metastatic melanoma is grim, with a 5-year survival rate of less than 10%. To date, only three agents have been approved for the treatment of metastatic disease, but these agents have low response rates. Interleukin-2, a cytokine that induces T-cell activation and proliferation, is associated with an overall response rate of 13 to 16%, and up to 6% of patients have a complete response that can be quite durable.3,4 A variety of agents have been combined with interleukin-2 in an effort to improve its efficacy, including chemotherapy and other cytokines.
Vaccination with the gp100:209-217(210M) peptide has resulted in very high levels of circulating T cells that were capable of recognizing and killing melanoma cancer cells in vitro, leading to the hypothesis that activation of these T cells with cytokines such as interleukin-2 could be synergistic. In a previous single-group, phase 2 study, patients with metastatic melanoma were immunized with the gp100:209-217(210M) peptide vaccine in Montanide ISA-51 (incomplete Freund's adjuvant), followed by high-dose interleukin-2, leading to objective clinical responses in 13 of 31 patients (42%).5 The fact that the response rate was apparently higher than that previously reported with interleukin-2 alone provided the impetus for the current randomized trial comparing vaccine plus interleukin-2 with interleukin-2 alone.
Methods
Study Design
The study was designed by the authors, in consultation with the study sponsor, the Cancer Therapy Evaluation Program (CTEP) of the National Cancer Institute (NCI). The primary end point of the trial was the rate of clinical response. Secondary end points included progression-free survival, toxic effects, immunologic response, and quality of life. After providing written informed consent, patients were randomly assigned, in a 1:1 ratio, to receive a high-dose bolus of interleukin-2 alone every 8 hours (Proleukin, Prometheus; provided through the patients' health plans), or gp100:209-217(210M) plus Montanide ISA-51 (provided by the CTEP), given once per cycle, and the same high-dose interleukin-2 regimen beginning the second day of the cycle. Patients were stratified according to the site of disease (cutaneous or subcutaneous only vs. any site). Stratified randomization was performed with the use of random block sizes to ensure balance with respect to a potentially important prognostic feature. The full protocol, including the statistical analysis plan, is available with the full text of this article at NEJM.org.
The data were collected and the study was monitored by EMMES, a contract research organization. An independent data and safety monitoring board met annually and performed a planned interim analysis after 93 patients were enrolled. The data were analyzed by statisticians at EMMES and by the corresponding author. The first draft of the manuscript was prepared by the corresponding author. All the authors had input into the subsequent and final drafts and made the decision to submit the manuscript for publication. All the authors vouch for the accuracy of the data and for the fidelity of the study to the protocol. No pharmaceutical company had any role in the design of the study, the accrual or analysis of the data, or the preparation of the manuscript.
Patients
Patients were eligible for inclusion in the study if they had metastatic cutaneous melanoma, either stage IV or locally advanced stage III, and were HLA*A0201-positive (to allow presentation of the peptide vaccine to T cells). All genotyping for HLA status was performed at the National Institutes of Health HLA laboratory. All pathology slides were reviewed by pathologists at the NCI. All patients met the criteria for receiving high-dose interleukin-2 treatment and had no major cardiac, pulmonary, or renal diseases. Details regarding the inclusion criteria are provided in the Supplementary Appendix, available at NEJM.org.
Treatment
All patients received interleukin-2 at a dose of 720,000 IU per kilogram of body weight every 8 hours as an intravenous bolus. The vaccine group also received the HLA*A0201-restricted peptide gp100:209-217(210 M), amino acid sequence IMDQVPFSV (National Service Center [NSC] no. 683472). It was obtained from the CTEP under investigational-new-drug application BB6123 and was supplied in vials containing 1 mg of the peptide per milliliter of sterile water. Before administration in the subcutaneous tissues of the thigh, the peptide was mixed (with the use of a vortexer) with Montanide ISA-51 adjuvant (NSC no. 675756) provided by the CTEP under investigational-new-drug application BB5924.
Each patient was treated with interleukin-2, as tolerated, up to a maximum of 12 doses per cycle. Each cycle of treatment was repeated every 3 weeks, with 1 extra week added after every two cycles to allow for evaluation of the response. Patients with stable disease continued treatment for an additional two cycles. Patients with progressive disease or new sites of disease discontinued therapy.
Assessments
Tumor response was assessed every 6 weeks according to modified World Health Organization criteria (see the Supplementary Appendix). In vitro studies, in which peptide-specific T cells and CD4+foxp3+ T regulatory cells in the circulation were measured, were performed before the start of treatment and after the completion of four cycles of therapy (see the Supplementary Appendix). Toxic effects and adverse events were assessed according to the NCI Common Toxicity Criteria, version 2.0 (http://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcv20_4-30-992.pdf).
Statistical Analysis
We estimated that with 83 patients in each group, the study would have 80% power to detect a difference between the two groups, assuming a clinical response rate of 15% in the interleukin-2–only group3 and 35% in the vaccine–interleukin-2 group,5 at an overall alpha level of 0.05 (two-tailed). In order to account for patients who could not be evaluated, we aimed to enroll a total of 185 patients.
All the analyses presented were specified before the data were unblinded. A Wilcoxon rank-sum test was used for the between-group comparison of skewed continuous variables, a chi-square or Fisher's exact test for the comparison of categorical variables, and a log-rank test for the comparison of progression-free survival and overall survival. All reported P values are two-tailed. Bonferroni adjustment was applied in the analyses of toxic effects.
Results
Patients
Between June 6, 2000, and November 6, 2007, a total of 479 patients underwent HLA testing, and 185 patients at 21 institutions throughout the United States were randomly assigned to one of two groups. A total of 4 patients withdrew (1 in the interleukin-2–only group and 3 in the vaccine–interleukin-2 group), and 2 were ineligible (both in the vaccine–interleukin-2 group) and received no treatment. These 6 patients could not be evaluated for a response or for toxic effects. One patient received therapy off-protocol after receiving vaccine–interleukin-2 therapy and could not be evaluated for a response. All the patients were included in the analysis of progression-free survival and overall survival. In the interleukin-2–only group, 94 patients were enrolled, and 93 received treatment and could be evaluated for a response; in the vaccine–interleukin-2 group, 91 patients were enrolled, 86 received treatment, and 85 could be evaluated for a response.
The baseline characteristics of the patients in the two groups were well balanced (Table 1Table 1
Clinical Response
The primary objective of the study was to determine whether the addition of a peptide vaccine to high-dose interleukin-2 would result in a higher rate of clinical response than that with interleukin-2 alone. The response rate as assessed by the investigators was 10% (complete response, 2%; partial response, 8%) among the 93 patients receiving interleukin-2 alone and 20% (complete response, 11%; partial response, 9%) among the 85 patients receiving vaccine and interleukin-2 who could be evaluated for a response (P=0.05) (Table 2Table 2
Response to Treatment, as Assessed by Investigators and by Central Review.). After blinded central radiologic review, the response rate was 6% (complete response, 1%; partial response, 5%) among the patients receiving interleukin-2 alone and 16% (complete response, 9%; partial response, 7%) among the patients receiving vaccine and interleukin-2 (P=0.03) (Table 2). The difference between the two groups was greatest among patients with M1b metastatic disease (classified according to the tumor–node–metastasis [TNM] categorization for melanoma of the American Joint Committee on Cancer), because of lung involvement (0% vs. 25%, P=0.005); however, since in this study, stratification was not performed according to M1 disease status, the analysis of response in this small subgroup of patients has limited power and must be interpreted with caution.
A secondary objective of the study was to compare the two groups with respect to progression-free survival. The time to progression was defined as the time from randomization until documented progression or death from any cause. The median progression-free survival was 1.6 months (95% confidence interval [CI], 1.5 to 1.8) among patients receiving interleukin-2 alone and 2.2 months (95% CI, 1.7 to 3.9) among patients receiving vaccine and interleukin-2 (P=0.008) (Figure 1AFigure 1
Toxic Effects of Treatment
The grades 3 to 5 toxic effects that were observed over the course of all the cycles among the patients in both groups who received treatment were consistent with the expected side effects in patients receiving high-dose interleukin-2 (Table 3Table 3
Grades 3 to 5 Toxic Effects of Treatment over the Course of All Cycles.). With respect to most categories of toxicity, patients in the two groups had similar side effects, which were predominantly grade 3. There were more arrhythmias, more abnormalities of laboratory-test results, and more neurologic events among patients in the vaccine–interleukin-2 group than among patients in the interleukin-2–only group. (The P values have not been adjusted for multiple comparisons; therefore, at P=0.05, one result would be expected to be significant purely by chance.) Since these differences may have been related to the increased number of interleukin-2 treatment cycles received by patients in the vaccine–interleukin-2 group as compared with patients in the interleukin-2–only group (286 vs. 244), we also evaluated the toxic effects that were observed only in the first two cycles of therapy. When only the first two cycles of treatment were analyzed and adjusted for multiple comparisons, only the rate of arrhythmias remained significantly higher in the vaccine–interleukin-2 group than in the interleukin-2–only group (15% vs. 2%), owing predominantly to events of sinus tachycardia (5 vs. 1 grade 3 events) and supraventricular arrhythmia (5 vs. 1 grade 3 events). These toxic effects were transient and reversible in all the affected patients. Three treatment-related deaths occurred — one in the interleukin-2–only group and two in the vaccine–interleukin-2 group.
Results of In Vitro Studies
Immunologic analyses were performed before and after four cycles of treatment. Anti-peptide reactivity developed in none of the 12 patients in the interleukin-2–only group from whom samples could be evaluated, as compared with 7 of the 37 patients in the vaccine–interleukin-2 group from whom samples could be evaluated. There was no relationship between the development of anti-peptide reactivity and the objective clinical response.
Post-treatment levels of CD4+foxp3+ cells were higher in patients who had a clinical response to treatment than in those who did not have a response (16.84±2.22% vs. 11.08±1.01%, P=0.01). There was no effect of the vaccine on this difference. Additional results are provided in the Supplementary Appendix.
Discussion
This randomized study showed the clinical benefit of a vaccine in the treatment of patients with measurable metastatic melanoma. Patients receiving the HLA*A0201-restricted peptide gp100:209-217(210 M) with interleukin-2 were more than twice as likely to have a clinical response as those receiving interleukin-2 alone (Table 2). Though the response rate among the patients receiving interleukin-2 alone was lower than the rate of 16% reported initially from a limited number of experienced programs,3 our study was conducted at a large number of institutions, reflecting an outcome that is more likely to be achieved when experimental therapies are applied more widely. In addition, the response rates seen in this study are similar to those reported recently in a large, nonrandomized, single-institution study of interleukin-2 with a vaccine as compared with interleukin-2 without a vaccine (22% vs. 13%).4
After the initial report on the gp100 peptide vaccine5 that prompted this randomized trial, the Cytokine Working Group initiated a series of three phase 2 studies to confirm the efficacy of the vaccine.6 These three studies (involving 39 to 42 patients in each study) used the same peptide vaccine administered every 3 weeks but combined it with a lower dose of interleukin-2 than that used in our study, administered on variable schedules. The response rates ranged from 13% to 24%. These phase 2 studies did not include an interleukin-2–only control group, and consequently, conclusions about the efficacy of the vaccine itself could not be drawn.
The peptide vaccine added some toxic effects to those seen with interleukin-2 therapy. Aside from the skin reactions of redness, swelling, and pain at the local injection site, the vaccine was associated with higher incidences of transient, reversible sinus tachycardia and supraventricular arrhythmia than those seen with interleukin-2 alone. These side effects are within the expected range of side effects of high-dose interleukin-2; the reason for their increased frequency in the vaccine–interleukin-2 group is not known. The vaccine or the adjuvant may have induced additional circulating cytokines that could cause greater cardiac toxic effects.
A number of immune-suppressing molecules within the tumor microenvironment, as well as immune regulatory checkpoints, have been described that may inhibit antitumor T-cell responses in vivo.7,8 Overcoming these factors may be important for improving the efficacy of cancer vaccines. For example, the cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) molecule is capable of suppressing effector immune responses on T cells, and blockade of this molecule with the specific antibody ipilimumab has led to clinical responses in patients with melanoma.9 In a recent randomized trial, treatment with ipilimumab with or without the gp100 vaccine resulted in a survival advantage over treatment with the vaccine alone.10 In that study, the combination of ipilimumab with the vaccine was not superior to ipilimumab alone. It is not clear why we observed an improved response when we combined the gp100 vaccine with interleukin-2, whereas this was not seen when a similar vaccine was combined with ipilimumab. This disparity highlights the need for further validation of the conclusions from both of these studies but also points to potential differences in the mechanisms of action of interleukin-2 and ipilimumab. Among the numerous potential explanations for the difference is the possibility that immune responses in patients after anti–CTLA-4 therapy are largely dependent on CD4+ T cells; in contrast, the gp100 peptide vaccine was designed to stimulate CD8+ T cells. Anti–CTLA-4 antibody can augment CD8+ T-cell responses, and it can also independently augment CD4+ antitumor immune responses in murine models.11 Indeed, CD4+/ICOS+ T cells were shown to be increased in both the peripheral blood and tumor sites after anti–CTLA-4 antibody treatment in patients with bladder cancer.12 Additional studies are needed to understand these complex mechanisms of action.
In vitro studies of T-cell reactivity showed that some patients in the vaccine group had an increase in circulating gp100 reactive T cells after vaccination (see the Supplementary Appendix). However, the number of patients in whom gp100 reactive T cells developed was small, which is consistent with previous studies that noted that interleukin-2 decreased the number of antigen-specific T cells in the peripheral blood after vaccination,5,13,14 Perhaps this finding was the result of increased migration of antigen-specific T cells into the tumor after activation by interleukin-2. As with previous studies, circulating levels of antigen-specific T cells did not correlate with a clinical response, suggesting that future studies should incorporate additional assays and analysis of other areas, such as the tumor site. However, we noted an increase in T regulatory cells (CD4+foxp3+) in patients in both treatment groups who had a response to treatment (see the Supplementary Appendix). We postulate that this effect is related to interleukin-2. Although T regulatory cells are generally thought to be suppressive, they have been associated with improved survival in patients with colon cancer.15 We hypothesize that the increased levels of T regulatory cells in patients who had a response to treatment represent a counterregulatory response after a strong antitumor immune reaction; however, the increased levels may also be related to the timing of collection of the sample.
Our study showed that overall survival appeared to be somewhat better in the vaccine–interleukin-2 group in the period from 6 months through 3 years of follow-up (Figure 1B). Additional data are needed to ascertain whether the finding in our study was due to a direct effect of the vaccine or to the possibility that vaccinated patients were more responsive to salvage regimens or that the nature of progression differed between the two groups or that other factors were involved. Our study showed that a vaccine can enhance cytokine therapy in patients with melanoma and highlights the potential of using rational combinations of immune agents in treating patients with metastatic cancer.
Supported by the National Cancer Institute, Indiana University Health Goshen, Goshen Hospital and Health Care Foundation, Chiron, and Novartis.
Disclosure forms provided by the authors are available with the full text of this article at NEJM.org.
We thank Juliann Wu, M.S., of EMMES, Rockville, MD, for data management and statistics; Paul Duray, M.D., for review of pathology slides; Lien Ngo, M.S., Surgery Branch, National Cancer Institute (NCI), Bethesda, MD, for performing in vitro studies; personnel at the NCI Cancer Therapy Evaluation Program and Division of Cancer Treatment and Diagnosis for guidance and support for this project; and Jana Risemas for assistance with the preparation of the manuscript.
Source Information
From the Indiana University Health Goshen Center for Cancer Care, Goshen, IN (D.J.S.); Winship Cancer Institute, Emory University, Atlanta (D.H.L.); Oncology Specialists, Park Ridge, IL (J.M.R.); University of Alabama Health Services Foundation Comprehensive Cancer Center, Birmingham (R.M.C.); James Graham Brown Cancer Center, Louisville, KY (D.M.M.); St. Luke's Medical Center, Milwaukee (J.T.); Kaiser Permanente Medical Center, Riverside (F.G.), and Summit Medical Center, Oakland (J.B.) — both in California; St. Luke's Hospital, Bethlehem, PA (L.R.); Department of Surgical Pathology (M.J.M.), Surgery Branch (S.A.R.), and Cancer Therapy Evaluation Program (K.C.), National Cancer Institute (P.C.); and Department of Transfusion Medicine, Clinical Center and Trans-NIH Center for Human Immunology, National Institutes of Health (F.M.M.) — both in Bethesda, MD; EMMES Corp., Rockville, MD (D.V.); Mayo Clinic, Phoenix, AZ (B.P.); Ohio State University, Columbus (K.L.K.); Carolinas Medical Center, Charlotte, NC (R.L.W.); University of Colorado Denver, Denver (R.G.); Northwestern University (T.M.K.) and Rush University Medical Center (H.K.) — both in Chicago; Earle A. Chiles Research Institute, Portland, OR (B.C.); Christ Hospital, Cincinnati (P.D.L.); Atlantic Melanoma Center, Morristown, NJ (E.D.W.); University of South Florida, Tampa (D.S.R.); and M.D. Anderson Cancer Center, Houston (P.H.).
Address reprint requests to Dr. Schwartzentruber at IU Health Goshen Center for Cancer Care, 200 High Park Ave., Goshen, IN 46526, or at dschwart@iuhealth.org.
- References
References
1
Kantoff PW Higano CS Shore ND
Free Full Text | Web of Science | Medline2
Overwijk WW Theoret MR Restifo NP 3
Atkins MB Lotze MT Dutcher JP
Web of Science | Medline4
Smith FO Downey SG Klapper JA
CrossRef | Web of Science | Medline5
Rosenberg SA Yang JC Schwartzentruber DJ
CrossRef | Web of Science | Medline6
Sosman JA Carrillo C Urba WJ
CrossRef | Web of Science | Medline7
Korman AJ Peggs KS Allison JP
CrossRef | Web of Science | Medline8
Lizee G Cantu MA Hwu P
CrossRef | Web of Science | Medline9
Attia P Phan GQ Maker AV
CrossRef | Web of Science | Medline10
Hodi FS O'Day SJ McDermott DF
Free Full Text | Web of Science | Medline11
Quezada SA Simpson TR Peggs KS
CrossRef | Web of Science | Medline12
Liakou CI Kamat A Tang DN
CrossRef | Web of Science | Medline13
Slingluff CL Jr Petroni GR Yamshchikov GV
CrossRef | Web of Science | Medline14
Rosenberg SA Yang JC Schwartzentruber DJ
Web of Science | Medline15
Salama P Phillips M Grieu F
CrossRef | Web of Science | Medline
- Citing Articles (343)
Citing Articles
1
Adrian Bot, Elliot M. Berinstein, Neil L. Berinstein. . 2018. Cancer Vaccines. Plotkin's Vaccines, 161-184.e6.
CrossRef2
Emiliano Manzo, Adele Cutignano, Dario Pagano, Carmela Gallo, Giusi Barra, Genoveffa Nuzzo, Clementina Sansone, Adrianna Ianora, Konrad Urbanek, Daniela Fenoglio, Francesca Ferrera, Cinzia Bernardi, Alessia Parodi, Giuseppe Pasquale, Antonio Leonardi, Gilberto Filaci, Raffaele De Palma, Angelo Fontana. . (2017) A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response. Scientific Reports 7:1.
CrossRef3
Carole Fournier, François Martin, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi, Lionel Apetoh. . (2017) Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology 33, 00-00.
CrossRef4
Willem W Overwijk. . (2017) Cancer vaccines in the era of checkpoint blockade: the magic is in the adjuvant. Current Opinion in Immunology 47, 103-109.
CrossRef5
Y Wang, G Zhang, J Jin, S Degan, Y Tameze, J Y Zhang. . (2017) MALT1 promotes melanoma progression through JNK/c-Jun signaling. Oncogenesis 6:7, e365.
CrossRef6
Vedran Brezar, Lylia Hani, Mathieu Surenaud, Audrey Hubert, Christine Lacabaratz, Jean-Daniel Lelièvre, Yves Levy, Nabila Seddiki, Guido Silvestri. . (2017) Negative modulation of suppressive HIV-specific regulatory T cells by IL-2 adjuvanted therapeutic vaccine. PLOS Pathogens 13:7, e1006489.
CrossRef7
Cong Luo, Jiayu Shen. . (2017) Research progress in advanced melanoma. Cancer Letters 397, 120-126.
CrossRef8
Y Sun, S Peng, A Yang, E Farmer, T-C Wu, C-F Hung. . (2017) Coinjection of IL2 DNA enhances E7-specific antitumor immunity elicited by intravaginal therapeutic HPV DNA vaccination with electroporation. Gene Therapy 24:7, 408-415.
CrossRef9
Dezhi Ni, Shuang Qing, Hui Ding, Hua Yue, Di Yu, Shuang Wang, Nana Luo, Zhiguo Su, Wei Wei, Guanghui Ma. . (2017) Biomimetically Engineered Demi-Bacteria Potentiate Vaccination against Cancer. Advanced Science 26, 1700083.
CrossRef10
Shuyun Dong, Tiefeng Xu, Peng Wang, Peng Zhao, Mingnan Chen. . (2017) Engineering of a self-adjuvanted iTEP-delivered CTL vaccine. Acta Pharmacologica Sinica 38:6, 914-923.
CrossRef11
José Mordoh, María Betina Pampena, Mariana Aris, Paula Alejandra Blanco, Mónica Lombardo, Erika María von Euw, Soledad Mac Keon, Michelle Yépez Crow, Alicia Inés Bravo, Juan Manuel O’Connor, Ana Gabriela Orlando, Franco Ramello, Estrella Mariel Levy, María Marcela Barrio. . (2017) Phase II Study of Adjuvant Immunotherapy with the CSF-470 Vaccine Plus Bacillus Calmette–Guerin Plus Recombinant Human Granulocyte Macrophage-Colony Stimulating Factor vs Medium-Dose Interferon Alpha 2B in Stages IIB, IIC, and III Cutaneous Melanoma Patients: A Single Institution, Randomized Study. Frontiers in Immunology 8.
CrossRef12
Udupi A. Ramagopal, Weifeng Liu, Sarah C. Garrett-Thomson, Jeffrey B. Bonanno, Qingrong Yan, Mohan Srinivasan, Susan C. Wong, Alasdair Bell, Shilpa Mankikar, Vangipuram S. Rangan, Shrikant Deshpande, Alan J. Korman, Steven C. Almo. . (2017) Structural basis for cancer immunotherapy by the first-in-class checkpoint inhibitor ipilimumab. Proceedings of the National Academy of Sciences 114:21, E4223-E4232.
CrossRef13
Stefano Persano, Maria L. Guevara, Zhaoqi Li, Junhua Mai, Mauro Ferrari, Pier Paolo Pompa, Haifa Shen. . (2017) Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials 125, 81-89.
CrossRef14
Dixon H. Xu, Ziwen Zhu, Huaping Xiao, Mark R. Wakefield, Qian Bai, Michael B. Nicholl, Vivi A. Ding, Yujiang Fang. . (2017) Unveil the mysterious mask of cytokine-based immunotherapy for melanoma. Cancer Letters 394, 43-51.
CrossRef15
Emilie Bernichon, Chloé Rancoule, Alexis Vallard, Julien Langrand-Escure, Benoîte Mery, Jean-Baptiste Guy, Nicolas Magné. . (2017) Immunothérapie : après le focus sur les voies de signalisation, l’activation d’un système. Bulletin du Cancer 104:5, 462-475.
CrossRef16
Amelia Aitken, Dominic Roy, Marie-Claude Bourgeois-Daigneault. . (2017) Taking a Stab at Cancer; Oncolytic Virus-Mediated Anti-Cancer Vaccination Strategies. Biomedicines 5:1, 3.
CrossRef17
Takafumi Minami, Naoki Matsumura, Koichi Sugimoto, Nobutaka Shimizu, Marco De Velasco, Masahiro Nozawa, Kazuhiro Yoshimura, Nanae Harashima, Mamoru Harada, Hirotsugu Uemura. . (2017) Hypoxia-inducing factor (HIF)-1α-derived peptide capable of inducing cancer-reactive cytotoxic T lymphocytes from HLA-A24+ patients with renal cell carcinoma. International Immunopharmacology 44, 197-202.
CrossRef18
D. Kee, G. McArthur. . (2017) Immunotherapy of melanoma. European Journal of Surgical Oncology (EJSO) 43:3, 594-603.
CrossRef19
Marzena Nguyen, Paula Dobosz. . (2017) New Frontiers in Melanoma Epigenetics—The More We Know, the More We Don’t Know. Epigenomes 1:1, 3.
CrossRef20
Gareth Rivalland, Andrew M. Scott, Thomas John. . (2017) Standard of care in immunotherapy trials: Challenges and considerations. Human Vaccines & Immunotherapeutics 19, 1-15.
CrossRef21
Jeffery Schlom, James L. Gulley, James W. Hodge. . 2017. Vaccines and Immunostimulants. Holland-Frei Cancer Medicine, 1-22.
CrossRef22
Motoki Miyazawa, Masahiro Katsuda, Hiroyuki Maguchi, Akio Katanuma, Hiroshi Ishii, Masato Ozaka, Kenji Yamao, Hiroshi Imaoka, Manabu Kawai, Seiko Hirono, Ken-ichi Okada, Hiroki Yamaue. . (2017) Phase II clinical trial using novel peptide cocktail vaccine as a postoperative adjuvant treatment for surgically resected pancreatic cancer patients. International Journal of Cancer 140:4, 973-982.
CrossRef23
Qi Zhang, Bo Zhu, Yongsheng Li. . (2017) Resolution of Cancer-Promoting Inflammation: A New Approach for Anticancer Therapy. Frontiers in Immunology 8.
CrossRef24
Richard Bright, Brendon J. Coventry, Nathan Eardley-Harris, Nancy Briggs. . (2017) Clinical Response Rates From Interleukin-2 Therapy for Metastatic Melanoma Over 30 Years’ Experience. Journal of Immunotherapy 40:1, 21-30.
CrossRef25
Andrew Zloza, Neal D. Dharmadhikari, Erica J. Huelsmann, Joseph R. Broucek, Tasha Hughes, Frederick J. Kohlhapp, Howard L. Kaufman. . (2017) Low-dose interleukin-2 impairs host anti-tumor immunity and inhibits therapeutic responses in a mouse model of melanoma. Cancer Immunology, Immunotherapy 66:1, 9-16.
CrossRef26
Rong-Fu Wang, Helen Y Wang. . (2017) Immune targets and neoantigens for cancer immunotherapy and precision medicine. Cell Research 27:1, 11-37.
CrossRef27
M.M. Strioga, N.T. Dobrovolskiene. . 2017. Dendritic Cells as Targets of Vaccines and Adjuvants. Immunopotentiators in Modern Vaccines, 43-64.
CrossRef28
Shigehisa Kitano, Ayumu Ito, Youngji Kim. . 2017. Immunotherapy for Renal Cell Cancer (RCC). Renal Cell Carcinoma, 295-317.
CrossRef29
Doug Schwartzentruber. . 2017. gp100. Cancer Therapeutic Targets, 261-266.
CrossRef30
Howard L. Kaufman, Benjamin Kelley, Eduardo Braun. . 2017. Interleukin-2. Cancer Therapeutic Targets, 323-334.
CrossRef31
Patrick M. Dillon, Craig L. Slingluff. . 2017. Peptide Vaccine: Overview. Cancer Therapeutic Targets, 427-439.
CrossRef32
David L. Chen, Cheryl Armstrong, Mariah R. Brown. . 2017. Immunobiology and Immune Based Therapies of Melanoma. Clinical and Basic Immunodermatology, 871-890.
CrossRef33
A.S. Morris, A. Wongrakpanich, S.M. Geary, A.K. Salem. . 2017. Microparticles and Nanoparticles for Cancer-Targeting Vaccines. Micro and Nanotechnology in Vaccine Development, 171-183.
CrossRef34
Benjamin Weide, Alexander Martens, Kilian Wistuba-Hamprecht, Henning Zelba, Ludwig Maier, Hans-Peter Lipp, Bernhard D. Klumpp, Daniel Soffel, Thomas K. Eigentler, Claus Garbe. . (2016) Combined treatment with ipilimumab and intratumoral interleukin-2 in pretreated patients with stage IV melanoma—safety and efficacy in a phase II study. Cancer Immunology, Immunotherapy 17.
CrossRef35
Hiep Khong, Willem W. Overwijk. . (2016) Adjuvants for peptide-based cancer vaccines. Journal for ImmunoTherapy of Cancer 4:1.
CrossRef36
Sofia Farkona, Eleftherios P. Diamandis, Ivan M. Blasutig. . (2016) Cancer immunotherapy: the beginning of the end of cancer?. BMC Medicine 14:1.
CrossRef37
Adam I Riker, Erika Bisgaard. . (2016) Current clinical trials for melanoma vaccines: where do we stand?. Melanoma Management 3:4, 255-257.
CrossRef38
Robert O Dillman, Gabriel I Nistor, Andrew N Cornforth. . (2016) Dendritic cell vaccines for melanoma: past, present and future. Melanoma Management 3:4, 273-289.
CrossRef39
Fenge Li, Caixia Chen, Tao Ju, Junqin Gao, Jun Yan, Peng Wang, Qiang Xu, Patrick Hwu, Xueming Du, Gregory Lizée. . (2016) Rapid tumor regression in an Asian lung cancer patient following personalized neo-epitope peptide vaccination. OncoImmunology 5:12, e1238539.
CrossRef40
N. Arenas-Ramirez, C. Zou, S. Popp, D. Zingg, B. Brannetti, E. Wirth, T. Calzascia, J. Kovarik, L. Sommer, G. Zenke, J. Woytschak, C. H. Regnier, A. Katopodis, O. Boyman. . (2016) Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Science Translational Medicine 8:367, 367ra166-367ra166.
CrossRef41
Michal Bassani-Sternberg, Eva Bräunlein, Richard Klar, Thomas Engleitner, Pavel Sinitcyn, Stefan Audehm, Melanie Straub, Julia Weber, Julia Slotta-Huspenina, Katja Specht, Marc E. Martignoni, Angelika Werner, Rüdiger Hein, Dirk H. Busch, Christian Peschel, Roland Rad, Jürgen Cox, Matthias Mann, Angela M. Krackhardt. . (2016) Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry. Nature Communications 7, 13404.
CrossRef42
Satoshi Wada, Erika Yada, Junya Ohtake, Yuki Fujimoto, Hidemi Uchiyama, Shintaro Yoshida, Tetsuro Sasada. . (2016) Current status and future prospects of peptide-based cancer vaccines. Immunotherapy 8:11, 1321-1333.
CrossRef43
Mohammed Dany, Rose Nganga, Alissar Chidiac, Edith Hanna, Sara Matar, Dirk Elston. . (2016) Advances in immunotherapy for melanoma management. Human Vaccines & Immunotherapeutics 12:10, 2501-2511.
CrossRef44
Kristian M. Koller, Wenge Wang, Todd D. Schell, Eugene M. Cozza, Kathleen M. Kokolus, Rogerio I. Neves, Heath B. Mackley, Colette Pameijer, Anna Leung, Bryan Anderson, Carol A. Mallon, Gavin Robertson, Joseph J. Drabick. . (2016) Malignant melanoma—The cradle of anti-neoplastic immunotherapy. Critical Reviews in Oncology/Hematology 106, 25-54.
CrossRef45
C. Y. Hu, Y. H. Zhang, T. Wang, L. Chen, Z. H. Gong, Y. S. Wan, Q. J. Li, Y. S. Li, B. Zhu. . (2016) Interleukin-2 reverses CD8 + T cell exhaustion in clinical malignant pleural effusion of lung cancer. Clinical & Experimental Immunology 186:1, 106-114.
CrossRef46
Gourav Dhiman, Neha Lohia, Sahil Jain, Manoj Baranwal. . (2016) Metadherin peptides containing CD4 + and CD8 + T cell epitopes as a therapeutic vaccine candidate against cancer. Microbiology and Immunology 60:9, 646-652.
CrossRef47
Andrea Guennoun, Heba Sidahmed, Cristina Maccalli, Barbara Seliger, Francesco M. Marincola, Davide Bedognetti. . (2016) Harnessing the immune system for the treatment of melanoma: current status and future prospects. Expert Review of Clinical Immunology 12:8, 879-893.
CrossRef48
Joanne Chia, Germaine Goh, Frederic Bard. . (2016) Short O-GalNAc glycans: regulation and role in tumor development and clinical perspectives. Biochimica et Biophysica Acta (BBA) - General Subjects 1860:8, 1623-1639.
CrossRef49
I. Giannini, D. A. Cutrignelli, L. Resta, A. Gentile, L. Vincenti. . (2016) Metastatic melanoma of the gallbladder: report of two cases and a review of the literature. Clinical and Experimental Medicine 16:3, 295-300.
CrossRef50
Masatoshi Hirayama, Yasuharu Nishimura. . (2016) The present status and future prospects of peptide-based cancer vaccines. International Immunology 28:7, 319-328.
CrossRef51
V. Weingärtner, N. Dargatz, C. Weber, D. Mueller, S. Stock, R. Voltz, J. Gaertner. . (2016) Patient reported outcomes in randomized controlled cancer trials in advanced disease: a structured literature review. Expert Review of Clinical Pharmacology 9:6, 821-829.
CrossRef52
Tao Jiang, Caicun Zhou, Shengxiang Ren. . (2016) Role of IL-2 in cancer immunotherapy. OncoImmunology 5:6, e1163462.
CrossRef53
Jenny Lee, Richard Kefford, Matteo Carlino. . (2016) PD-1 and PD-L1 inhibitors in melanoma treatment: past success, present application and future challenges. Immunotherapy 8:6, 733-746.
CrossRef54
Christian Lehmann, Lukas Heger, Gordon Heidkamp, Anna Baranska, Jennifer Lühr, Alana Hoffmann, Diana Dudziak. . (2016) Direct Delivery of Antigens to Dendritic Cells via Antibodies Specific for Endocytic Receptors as a Promising Strategy for Future Therapies. Vaccines 4:2, 8.
CrossRef55
Satoru Iwasa, Yasuhide Yamada, Yuji Heike, Hirokazu Shoji, Yoshitaka Honma, Nobukazu Komatsu, Satoko Matsueda, Akira Yamada, Michi Morita, Rin Yamaguchi, Natsuki Tanaka, Akihiko Kawahara, Masayoshi Kage, Shigeki Shichijo, Tetsuro Sasada, Kyogo Itoh. . (2016) Phase I study of a new cancer vaccine of ten mixed peptides for advanced cancer patients. Cancer Science 107:5, 590-600.
CrossRef56
Shailendra K. Gupta, Tanushree Jaitly, Ulf Schmitz, Gerold Schuler, Olaf Wolkenhauer, Julio Vera. . (2016) Personalized cancer immunotherapy using Systems Medicine approaches. Briefings in Bioinformatics 17:3, 453-467.
CrossRef57
Yuya Imamura, Miwa Haruta, Yusuke Tomita, Keiko Matsumura, Tokunori Ikeda, Akira Yuno, Masatoshi Hirayama, Hideki Nakayama, Hiroshi Mizuta, Yasuharu Nishimura, Satoru Senju, Natalia Lapteva. . (2016) Generation of Large Numbers of Antigen-Expressing Human Dendritic Cells Using CD14-ML Technology. PLOS ONE 11:4, e0152384.
CrossRef58
K. Dietrich, M. Theobald. . (2016) Immunonkologische Therapiestrategien. best practice onkologie 11:2, 22-29.
CrossRef59
Ziqiang Zhu, Wei Liu, Vladimir Gotlieb. . (2016) The rapidly evolving therapies for advanced melanoma—Towards immunotherapy, molecular targeted therapy, and beyond. Critical Reviews in Oncology/Hematology 99, 91-99.
CrossRef60
Asad Javed, Shingo Sato, Takami Sato. . (2016) Autologous melanoma cell vaccine using monocyte-derived dendritic cells (NBS20/eltrapuldencel-T). Future Oncology 12:6, 751-762.
CrossRef61
Y. Najima, M. Tomizawa-Murasawa, Y. Saito, T. Watanabe, R. Ono, T. Ochi, N. Suzuki, H. Fujiwara, O. Ohara, L. D. Shultz, M. Yasukawa, F. Ishikawa. . (2016) Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood 127:6, 722-734.
CrossRef62
Nayoung Lee, Labib R. Zakka, Martin C. Mihm, Tobias Schatton. . (2016) Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. Pathology 48:2, 177-187.
CrossRef63
Ryan J. Davey, Andre van der Westhuizen, Nikola A. Bowden. . (2016) Metastatic melanoma treatment: Combining old and new therapies. Critical Reviews in Oncology/Hematology 98, 242-253.
CrossRef64
Kalijn F Bol, Erik H J G Aarntzen, Florentien E M in 't Hout, Gerty Schreibelt, Jeroen H A Creemers, W Joost Lesterhuis, Winald R Gerritsen, Dirk J Grunhagen, Cornelis Verhoef, Cornelis J A Punt, Johannes J Bonenkamp, Johannes H W de Wilt, Carl G Figdor, I Jolanda M de Vries. . (2016) Favorable overall survival in stage III melanoma patients after adjuvant dendritic cell vaccination. OncoImmunology 5:1, e1057673.
CrossRef65
K. Dietrich, M. Theobald. . (2016) Immunonkologische Therapiestrategien. Der Onkologe 22:1, 30-39.
CrossRef66
Cara Haymaker, Geok Choo Sim, Marie-Andree Forget, Jie Qing Chen, Chantale Bernatchez, Laszlo Radvanyi. . 2016. The Role of the Immune System and Immunoregulatory Mechanisms Relevant to Melanoma. Genetics of Melanoma, 31-65.
CrossRef67
Karrie K. Wong, WeiWei Aileen Li, David J. Mooney, Glenn Dranoff. . 2016. Advances in Therapeutic Cancer Vaccines. Tumor Immunology, 191-249.
CrossRef68
Anand Rotte, Madhuri Bhandaru. . 2016. Promising Immunotherapeutic Approaches in Clinical Trials. Immunotherapy of Melanoma, 351-416.
CrossRef69
Michal Lotem, Sharon Merims, Stephen Frank, Tamar Hamburger, Aviram Nissan, Luna Kadouri, Jonathan Cohen, Ravid Straussman, Galit Eisenberg, Shoshana Frankenburg, Einat Carmon, Bilal Alaiyan, Shlomo Shneibaum, Zeynep Ozge Ayyildiz, Murat Isbilen, Kerem Mert Senses, Ilan Ron, Hanna Steinberg, Yoav Smith, Eitan Shiloni, Ali Osmay Gure, Tamar Peretz. . (2016) Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade. Journal of Immunology Research 2016, 1-12.
CrossRef70
U. Dhagat, T.L. Nero, W.L. Kan, T.R. Hercus, S.E. Broughton, N.A. de Weerd, B.J. Jenkins, A. Mansell, M.A. Guthridge, P.J. Hertzog, A.F. Lopez, M.W. Parker. . 2016. Cytokine Receptors and Their Ligands. Encyclopedia of Cell Biology, 22-36.
CrossRef71
Erika Schneble, G. Travis Clifton, Diane F. Hale, George E. Peoples. . 2016. Peptide-Based Cancer Vaccine Strategies and Clinical Results. Vaccine Design, 797-817.
CrossRef72
Catia Traversari, Vincenzo Russo. . 2016. T Cells as Antigen Carriers for Anti-tumor Vaccination. Tumor Immunology, 97-104.
CrossRef73
Eran Ophir, Sara Bobisse, George Coukos, Alexandre Harari, Lana E. Kandalaft. . (2016) Personalized approaches to active immunotherapy in cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1865:1, 72-82.
CrossRef74
Isabella C. Glitza, Dae Won Kim, Young Kwang Chae, Kevin B. Kim. . 2016. Targeted Therapy in Melanoma. Genetics of Melanoma, 237-265.
CrossRef75
Siddarth Chandrasekaran, Maxine F. Chan, Jiahe Li, Michael R. King. . (2016) Super natural killer cells that target metastases in the tumor draining lymph nodes. Biomaterials 77, 66-76.
CrossRef76
Thomas Wieder, Ellen Brenner, Heidi Braumüller, Martin Röcken. . (2016) Immuntherapie des Melanoms: Wirksamkeit und Wirkungsmechanismen. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:1, 28-37.
CrossRef77
Thomas Wieder, Ellen Brenner, Heidi Braumüller, Martin Röcken. . (2016) Immunotherapy of melanoma: efficacy and mode of action. JDDG: Journal der Deutschen Dermatologischen Gesellschaft 14:1, 28-36.
CrossRef78
Pamela L. Beatty, Olivera J. Finn. . 2016. Therapeutic and Prophylactic Cancer Vaccines. Encyclopedia of Immunobiology, 542-549.
CrossRef79
S. Krishnamurthy, M. K. Gnanasammandhan, C. Xie, K. Huang, M. Y. Cui, J. M. Chan. . (2016) Monocyte cell membrane-derived nanoghosts for targeted cancer therapy. Nanoscale 8:13, 6981-6985.
CrossRef80
Gregory T. Wurz, Chiao-Jung Kao, Michael W. DeGregorio. . (2016) Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Therapeutic Advances in Medical Oncology 8:1, 4-31.
CrossRef81
Adriana G. Ramirez, Nolan A. Wages, Yinin Hu, Mark E. Smolkin, Craig L. Slingluff. . (2015) Defining the effects of age and gender on immune response and outcomes to melanoma vaccination: a retrospective analysis of a single-institution clinical trials’ experience. Cancer Immunology, Immunotherapy 64:12, 1531-1539.
CrossRef82
Paolo A. Ascierto, Michael Atkins, Carlo Bifulco, Gerardo Botti, Alistair Cochran, Michael Davies, Sandra Demaria, Reinhard Dummer, Soldano Ferrone, Silvia Formenti, Thomas F. Gajewski, Claus Garbe, Samir Khleif, Rolf Kiessling, Roger Lo, Paul Lorigan, Grant Mc Arthur, Giuseppe Masucci, Ignacio Melero, Martin Mihm, Giuseppe Palmieri, Giorgio Parmiani, Igor Puzanov, Pedro Romero, Bastian Schilling, Barbara Seliger, David Stroncek, Janis Taube, Sara Tomei, Hassane M. Zarour, Alessandro Testori, Ena Wang, Jérôme Galon, Gennaro Ciliberto, Nicola Mozzillo, Francesco M. Marincola, Magdalena Thurin. . (2015) Future perspectives in melanoma research: meeting report from the “Melanoma Bridge”: Napoli, December 3rd–6th 2014. Journal of Translational Medicine 13:1.
CrossRef83
Vishwanath Sathyanarayanan, Sattva S. Neelapu. . (2015) Cancer immunotherapy: Strategies for personalization and combinatorial approaches. Molecular Oncology 9:10, 2043-2053.
CrossRef84
Ronnie H. Fang, Ashley V. Kroll, Liangfang Zhang. . (2015) Nanoparticle-Based Manipulation of Antigen-Presenting Cells for Cancer Immunotherapy. Small 11:41, 5483-5496.
CrossRef85
Susanne Hofmann, Andrew Mead, Aleksandrs Malinovskis, Nicola R. Hardwick, Barbara-ann Guinn. . (2015) Analogue peptides for the immunotherapy of human acute myeloid leukemia. Cancer Immunology, Immunotherapy 64:11, 1357-1367.
CrossRef86
Yan Zhao, Meirong Huo, Zhenghong Xu, Yuhua Wang, Leaf Huang. . (2015) Nanoparticle delivery of CDDO-Me remodels the tumor microenvironment and enhances vaccine therapy for melanoma. Biomaterials 68, 54-66.
CrossRef87
Susanne H.C. Baumeister, Glenn Dranoff. . 2015. Principles of Targeted Immunotherapy. Targeted Therapy in Translational Cancer Research, 27-38.
CrossRef88
Natascha Hermann-Kleiter, Victoria Klepsch, Stephanie Wallner, Kerstin Siegmund, Sebastian Klepsch, Selma Tuzlak, Andreas Villunger, Sandra Kaminski, Christa Pfeifhofer-Obermair, Thomas Gruber, Dominik Wolf, Gottfried Baier. . (2015) The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance. Cell Reports 12:12, 2072-2085.
CrossRef89
Lieping Chen, Xue Han. . (2015) Anti–PD-1/PD-L1 therapy of human cancer: past, present, and future. Journal of Clinical Investigation 125:9, 3384-3391.
CrossRef90
Yoshie Kametani, Asuka Miyamoto, Banri Tsuda, Yutaka Tokuda. . (2015) B Cell Epitope-Based Vaccination Therapy. Antibodies 4:3, 225-239.
CrossRef91
Roberta Zappasodi, Taha Merghoub. . (2015) Alphavirus-based vaccines in melanoma: rationale and potential improvements in immunotherapeutic combinations. Immunotherapy 7:9, 981-997.
CrossRef92
Iuliana Nenu, Diana Tudor, Adriana Gabriela Filip, Ioana Baldea. . (2015) Current position of TNF-α in melanomagenesis. Tumor Biology 36:9, 6589-6602.
CrossRef93
Cornelis J.M. Melief, Thorbald van Hall, Ramon Arens, Ferry Ossendorp, Sjoerd H. van der Burg. . (2015) Therapeutic cancer vaccines. Journal of Clinical Investigation 125:9, 3401-3412.
CrossRef94
Yuchen Fan, James Moon. . (2015) Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy. Vaccines 3:3, 662-685.
CrossRef95
Kevin B Kim. . (2015) Nivolumab in the treatment of advanced melanoma. Expert Opinion on Orphan Drugs 3:8, 945-956.
CrossRef96
Wendy WJ Unger, Christian T Mayer, Steef Engels, Christina Hesse, Maurizio Perdicchio, Franz Puttur, Ingeborg Streng-Ouwehand, Manja Litjens, Hakan Kalay, Luciana Berod, Tim Sparwasser, Yvette van Kooyk. . (2015) Antigen targeting to dendritic cells combined with transient regulatory T cell inhibition results in long-term tumor regression. OncoImmunology 4:8, e970462.
CrossRef97
Adam J Cooper, Matteo S Carlino, Richard F Kefford. . (2015) Immune checkpoint inhibitors in melanoma. Melanoma Management 2:3, 267-284.
CrossRef98
Theofanis Floros, Ahmad A. Tarhini. . (2015) Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12. Seminars in Oncology 42:4, 539-548.
CrossRef99
Zili Wang, Esteban Celis. . (2015) STING activator c-di-GMP enhances the anti-tumor effects of peptide vaccines in melanoma-bearing mice. Cancer Immunology, Immunotherapy 64:8, 1057-1066.
CrossRef100
Joseph Obeid, Yinin Hu, Craig L. Slingluff. . (2015) Vaccines, Adjuvants, and Dendritic Cell Activators—Current Status and Future Challenges. Seminars in Oncology 42:4, 549-561.
CrossRef101
Haydn T Kissick, Martin G Sanda. . (2015) The role of active vaccination in cancer immunotherapy: lessons from clinical trials. Current Opinion in Immunology 35, 15-22.
CrossRef102
Adeolu Oyemade Adegoke, Michael David Grant. . (2015) Enhancing Human Immunodeficiency Virus-Specific CD8+ T Cell Responses with Heteroclitic Peptides. Frontiers in Immunology 6.
CrossRef103
Julie Delyon, Michele Maio, Celeste Lebbé. . (2015) The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. Seminars in Oncology 42:3, 387-401.
CrossRef104
Alice O. Kamphorst, Koichi Araki, Rafi Ahmed. . (2015) Beyond adjuvants: Immunomodulation strategies to enhance T cell immunity. Vaccine 33, B21-B28.
CrossRef105
Robert O. Dillman, Edward F. McClay, Neil M. Barth, Thomas T. Amatruda, Lee S. Schwartzberg, Khosrow Mahdavi, Cristina de Leon, Robin E. Ellis, Carol DePriest. . (2015) Dendritic Versus Tumor Cell Presentation of Autologous Tumor Antigens for Active Specific Immunotherapy in Metastatic Melanoma: Impact on Long-Term Survival by Extent of Disease at the Time of Treatment. Cancer Biotherapy and Radiopharmaceuticals 30:5, 187-194.
CrossRef106
Yukiko Kiniwa, Jiang Li, Mingjun Wang, Chuang Sun, Jeffrey E. Lee, Rong-Fu Wang, Helen Y. Wang, Xue-feng Bai. . (2015) Identification of DRG-1 As a Melanoma-Associated Antigen Recognized by CD4+ Th1 Cells. PLOS ONE 10:5, e0124094.
CrossRef107
Cheryl Lai-Lai Chiang, Klara Balint, George Coukos, Lana E Kandalaft. . (2015) Potential approaches for more successful dendritic cell-based immunotherapy. Expert Opinion on Biological Therapy 15:4, 569-582.
CrossRef108
Jonathan Pol, Norma Bloy, Aitziber Buqué, Alexander Eggermont, Isabelle Cremer, Catherine Sautès-Fridman, Jérôme Galon, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. . (2015) Trial Watch: Peptide-based anticancer vaccines. OncoImmunology 4:4, e974411.
CrossRef109
Jun Li, Yujue Wang, Ruijing Liang, Xiangjie An, Ke Wang, Guanxin Shen, Yating Tu, Jintao Zhu, Juan Tao. . (2015) Recent advances in targeted nanoparticles drug delivery to melanoma. Nanomedicine: Nanotechnology, Biology and Medicine 11:3, 769-794.
CrossRef110
Hiroyasu Makuuchi, Kaiyo Takubo, Akio Yanagisawa, Soichiro Yamamoto. . (2015) Esophageal malignant melanoma: analysis of 134 cases collected by the Japan Esophageal Society. Esophagus 12:2, 158-169.
CrossRef111
Masanori Noguchi, Gaku Arai, Kazumasa Matsumoto, Seiji Naito, Fukuko Moriya, Shigetaka Suekane, Nobukazu Komatsu, Satoko Matsueda, Tetsuro Sasada, Akira Yamada, Tatsuyuki Kakuma, Kyogo Itoh. . (2015) Phase I trial of a cancer vaccine consisting of 20 mixed peptides in patients with castration-resistant prostate cancer: dose-related immune boosting and suppression. Cancer Immunology, Immunotherapy 64:4, 493-505.
CrossRef112
Oliver Klein, Ian D. Davis, Grant A. McArthur, Li Chen, Andrew Haydon, Phillip Parente, Nektaria Dimopoulos, Heather Jackson, Kun Xiao, Eugene Maraskovsky, Wendie Hopkins, Rodica Stan, Weisan Chen, Jonathan Cebon. . (2015) Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma. Cancer Immunology, Immunotherapy 64:4, 507-518.
CrossRef113
Megan M. Saraceni, Nikhil I. Khushalani, Anthony Jarkowski. . (2015) Immunotherapy in Melanoma. Journal of Pharmacy Practice 28:2, 193-203.
CrossRef114
Yuji Kaneko, Naoki Tajiri, Meaghan Staples, Stephanny Reyes, Diego Lozano, Paul R. Sanberg, Thomas B. Freeman, Harry Van Loveren, Seung U. Kim, Cesar V. Borlongan. . (2015) Bone Marrow-Derived Stem Cell Therapy for Metastatic Brain Cancers. Cell Transplantation 24:4, 625-630.
CrossRef115
Alexios Matikas, Dimitrios Mavroudis. . (2015) Beyond CTLA-4: novel immunotherapy strategies for metastatic melanoma. Future Oncology 11:6, 997-1009.
CrossRef116
Sofie Wilgenhof, Jurgen Corthals, An M. T. Van Nuffel, Daphné Benteyn, Carlo Heirman, Aude Bonehill, Kris Thielemans, Bart Neyns. . (2015) Long-term clinical outcome of melanoma patients treated with messenger RNA-electroporated dendritic cell therapy following complete resection of metastases. Cancer Immunology, Immunotherapy 64:3, 381-388.
CrossRef117
Jenny Fernando, Satish Kumar. . (2015) Principles of cancer treatment by immunotherapy. Surgery (Oxford) 33:3, 117-121.
CrossRef118
Danka J. F. Stuijver, Erica Romualdi, Bregje van Zaane, Leon Bax, Harry R. Büller, Victor E. A. Gerdes, Alessandro Squizzato. . (2015) Under-reporting of venous and arterial thrombotic events in randomized clinical trials: a meta-analysis. Internal and Emergency Medicine 10:2, 219-246.
CrossRef119
Zhiya Ya, Yared Hailemichael, Willem Overwijk, Nicholas P. Restifo. . 2015. Mouse Model for Pre-Clinical Study of Human Cancer Immunotherapy. Current Protocols in Immunology, 20.1.1-20.1.43.
CrossRef120
Derick Okwan-Duodu, Brian P. Pollack, David Lawson, Mohammad K. Khan. . (2015) Role of Radiation Therapy as Immune Activator in the Era of Modern Immunotherapy for Metastatic Malignant Melanoma. American Journal of Clinical Oncology 38:1, 119-125.
CrossRef121
Kun Shao, Santiswarup Singha, Xavier Clemente-Casares, Sue Tsai, Yang Yang, Pere Santamaria. . (2015) Nanoparticle-Based Immunotherapy for Cancer. ACS Nano 9:1, 16-30.
CrossRef122
Daniel J. Kowalewski, Heiko Schuster, Linus Backert, Claudia Berlin, Stefan Kahn, Lothar Kanz, Helmut R. Salih, Hans-Georg Rammensee, Stefan Stevanovic, Juliane Sarah Stickel. . (2015) HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL). Proceedings of the National Academy of Sciences 112:2, E166-E175.
CrossRef123
J. David Peske, Amber B. Woods, Victor H. Engelhard. . 2015. Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment. Immunotherapy of Cancer, 263-307.
CrossRef124
Megan A. McNamara, Smita K. Nair, Eda K. Holl. . (2015) RNA-Based Vaccines in Cancer Immunotherapy. Journal of Immunology Research 2015, 1-9.
CrossRef125
Michelle H. Nelson, Marshall A. Diven, Logan W. Huff, Chrystal M. Paulos. . (2015) Harnessing the Microbiome to Enhance Cancer Immunotherapy. Journal of Immunology Research 2015, 1-12.
CrossRef126
Maria Libera Ascierto, Salvador Martin Algarra, Ignacio Melero, Paolo A. Ascierto. . 2015. Enhancing T Cell Performance Against Cancer in Combination Treatment Strategies. Developments in T Cell Based Cancer Immunotherapies, 245-258.
CrossRef127
Matthew R. Kudelka, Tongzhong Ju, Jamie Heimburg-Molinaro, Richard D. Cummings. . 2015. Simple Sugars to Complex Disease—Mucin-Type O-Glycans in Cancer. Glycosylation and Cancer, 53-135.
CrossRef128
Davide Bedognetti, Sara Tomei, Wouter Hendrickx, Francesco M. Marincola, Ena Wang. . 2015. Toward the Identification of Genetic Determinants of Responsiveness to Cancer Immunotherapy. Developments in T Cell Based Cancer Immunotherapies, 99-127.
CrossRef129
Teresa Ramirez-Montagut. . 2015. Cancer Vaccines. Novel Approaches and Strategies for Biologics, Vaccines and Cancer Therapies, 365-388.
CrossRef130
Monika Håkerud, Pål K. Selbo, Ying Waeckerle-Men, Emmanuel Contassot, Piotr Dziunycz, Thomas M. Kündig, Anders Høgset, Pål Johansen. . (2015) Photosensitisation facilitates cross-priming of adjuvant-free protein vaccines and stimulation of tumour-suppressing CD8 T cells. Journal of Controlled Release 198, 10-17.
CrossRef131
Jooeun Bae, Mehmet Samur, Aditya Munshi, Teru Hideshima, Derin Keskin, Alec Kimmelman, Ann-Hwee Lee, Glen Dranoff, Kenneth C Anderson, Nikhil C Munshi. . (2014) Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. OncoImmunology 3:12, e970914.
CrossRef132
Mira Patel, Jennifer Kim, Jacob Ruzevick, Gordon Li, Michael Lim. . (2014) The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy. Cancers 6:4, 1953-1985.
CrossRef133
Osama E. Rahma, Zaw W. Myint, Bassam Estfan. . (2014) Dendritic Cell Cancer Vaccines for Treatment of Colon Cancer. Current Colorectal Cancer Reports 10:4, 470-476.
CrossRef134
Mingjun Wang, Bingnan Yin, Helen Y Wang, Rong-Fu Wang. . (2014) Current advances in T-cell-based cancer immunotherapy. Immunotherapy 6:12, 1265-1278.
CrossRef135
Jie Yang, Qing Zhang, Ke Li, Hong Yin, Jun‑Nian Zheng. . (2014) Composite peptide‑based vaccines for cancer immunotherapy (Review). International Journal of Molecular Medicine.
CrossRef136
Angus G Dalgleish. . (2014) Vaccines versus immunotherapy: Overview of approaches in deciding between options. Human Vaccines & Immunotherapeutics 10:11, 3369-3374.
CrossRef137
Giorgio Parmiani, Vincenzo Russo, Cristina Maccalli, Danilo Parolini, Nathalie Rizzo, Michele Maio. . (2014) Peptide-based vaccines for cancer therapy. Human Vaccines & Immunotherapeutics 10:11, 3175-3178.
CrossRef138
Julie Rowe, Putao Cen. . (2014) TroVax in colorectal cancer. Human Vaccines & Immunotherapeutics 10:11, 3196-3200.
CrossRef139
Giorgio Parmiani, Lorenzo Pilla, Angelo Corti, Claudio Doglioni, Carolina Cimminiello, Matteo Bellone, Danilo Parolini, Vincenzo Russo, Filippo Capocefalo, Cristina Maccalli. . (2014) A pilot Phase I study combining peptide-based vaccination and NGR-hTNF vessel targeting therapy in metastatic melanoma. OncoImmunology 3:11, e963406.
CrossRef140
Yinin Hu, Mark E. Smolkin, Emily J. White, Gina R. Petroni, Patrice Y. Neese, Craig L. Slingluff. . (2014) Inflammatory Adverse Events are Associated with Disease-Free Survival after Vaccine Therapy among Patients with Melanoma. Annals of Surgical Oncology 21:12, 3978-3984.
CrossRef141
Robert O Dillman. . (2014) Is vaccine research still relevant for metastatic melanoma?. Melanoma Management 1:2, 91-94.
CrossRef142
André Ballesteros-Tato. . (2014) Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases. Immunotherapy 6:11, 1207-1220.
CrossRef143
Avi Robinson-Mosher, Jan-Hung Chen, Jeffrey Way, Pamela A. Silver. . (2014) Designing Cell-Targeted Therapeutic Proteins Reveals the Interplay between Domain Connectivity and Cell Binding. Biophysical Journal 107:10, 2456-2466.
CrossRef144
Masaki Ito, Kazumi Hayashi, Eru Adachi, Tamiko Minamisawa, Sadamu Homma, Shigeo Koido, Kiyotaka Shiba, Yeonseok Chung. . (2014) Combinatorial Contextualization of Peptidic Epitopes for Enhanced Cellular Immunity. PLoS ONE 9:10, e110425.
CrossRef145
Sampada Sawant, Ranjita Shegokar. . (2014) Cancer research and therapy: Where are we today?. International Journal of Cancer Therapy and Oncology 2:4, 020408.
CrossRef146
Junko Ozao-Choy, Delphine J. Lee, Mark B. Faries. . (2014) Melanoma Vaccines. Surgical Clinics of North America 94:5, 1017-1030.
CrossRef147
Hong-Mei Xu. . (2014) Th1 cytokine-based immunotherapy for cancer. Hepatobiliary & Pancreatic Diseases International 13:5, 482-494.
CrossRef148
Vernon K. Sondak, Geoffrey T. Gibney. . (2014) Indications and Options for Systemic Therapy in Melanoma. Surgical Clinics of North America 94:5, 1049-1058.
CrossRef149
David McDermott, Celeste Lebbé, F. Stephen Hodi, Michele Maio, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson, Charles M. Balch. . (2014) Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. Cancer Treatment Reviews 40:9, 1056-1064.
CrossRef150
Agata Kosmaczewska. . (2014) Low-Dose Interleukin-2 Therapy: A Driver of an Imbalance between Immune Tolerance and Autoimmunity. International Journal of Molecular Sciences 15:10, 18574-18592.
CrossRef151
Takuro Saito, Hisashi Wada, Makoto Yamasaki, Hiroshi Miyata, Hiroyoshi Nishikawa, Eiichi Sato, Shinichi Kageyama, Hiroshi Shiku, Masaki Mori, Yuichiro Doki. . (2014) High expression of MAGE-A4 and MHC class I antigens in tumor cells and induction of MAGE-A4 immune responses are prognostic markers of CHP-MAGE-A4 cancer vaccine. Vaccine 32:45, 5901-5907.
CrossRef152
S. S. Neelapu, L. W. Kwak. . (2014) Rush Hour Traffic: Directing T Cells to Tumor. JNCI Journal of the National Cancer Institute 106:11, dju301-dju301.
CrossRef153
E. A. Mittendorf, G. T. Clifton, J. P. Holmes, E. Schneble, D. van Echo, S. Ponniah, G. E. Peoples. . (2014) Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients. Annals of Oncology 25:9, 1735-1742.
CrossRef154
Yared Hailemichael, Willem W. Overwijk. . (2014) Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. The International Journal of Biochemistry & Cell Biology 53, 46-50.
CrossRef155
Geok Choo Sim, Laszlo Radvanyi. . (2014) The IL-2 cytokine family in cancer immunotherapy. Cytokine & Growth Factor Reviews 25:4, 377-390.
CrossRef156
Betty S. Jiang, Georgia M. Beasley, Paul J. Speicher, Paul J. Mosca, Michael A. Morse, Brent Hanks, April Salama, Douglas S. Tyler. . (2014) Immunotherapy Following Regional Chemotherapy Treatment of Advanced Extremity Melanoma. Annals of Surgical Oncology 21:8, 2525-2531.
CrossRef157
Ignacio Melero, Gustav Gaudernack, Winald Gerritsen, Christoph Huber, Giorgio Parmiani, Suzy Scholl, Nicholas Thatcher, John Wagstaff, Christoph Zielinski, Ian Faulkner, Håkan Mellstedt. . (2014) Therapeutic vaccines for cancer: an overview of clinical trials. Nature Reviews Clinical Oncology 11:9, 509-524.
CrossRef158
Håkan Mellstedt, Gustav Gaudernack, Winald R Gerritsen, Christoph Huber, Ignacio Melero, Giorgio Parmiani, Suzy Scholl, Nicholas Thatcher, John Wagstaff, Christoph Zielinski. . (2014) Awareness and understanding of cancer immunotherapy in Europe. Human Vaccines & Immunotherapeutics 10:7, 1828-1835.
CrossRef159
Marius M. Strioga, Adas Darinskas, Vita Pasukoniene, Agata Mlynska, Valerijus Ostapenko, Virgil Schijns. . (2014) Xenogeneic therapeutic cancer vaccines as breakers of immune tolerance for clinical application: To use or not to use?. Vaccine 32:32, 4015-4024.
CrossRef160
Ghaith Bakdash, Inge Schreurs, Gerty Schreibelt, Jurjen Tel. . (2014) Crosstalk between dendritic cell subsets and implications for dendritic cell-based anticancer immunotherapy. Expert Review of Clinical Immunology 10:7, 915-926.
CrossRef161
Giulio Tosti, Emilia Cocorocchio, Elisabetta Pennacchioli, Pier Francesco Ferrucci, Alessandro Testori, Chiara Martinoli. . (2014) Heat-shock proteins-based immunotherapy for advanced melanoma in the era of target therapies and immunomodulating agents. Expert Opinion on Biological Therapy 14:7, 955-967.
CrossRef162
Mary Ann N. Johnson, April W. Armstrong. . 2014. Treatment of Cutaneous Melanoma. Evidence-Based Dermatology, 231-240.
CrossRef163
Vikram C. Gorantla, John M. Kirkwood. . (2014) State of Melanoma. Hematology/Oncology Clinics of North America 28:3, 415-435.
CrossRef164
Patrick A. Ott, Edward F. Fritsch, Catherine J. Wu, Glenn Dranoff. . (2014) Vaccines and Melanoma. Hematology/Oncology Clinics of North America 28:3, 559-569.
CrossRef165
Elizabeth I. Buchbinder, David F. McDermott. . (2014) Interferon, Interleukin-2, and Other Cytokines. Hematology/Oncology Clinics of North America 28:3, 571-583.
CrossRef166
Sandro Pasquali, Richard Kefford, Vanna Chiarion Sileni, Donato Nitti, Carlo Riccardo Rossi, Pierluigi Pilati, Simone Mocellin, Simone Mocellin. . 2014. Systemic treatments for metastatic cutaneous melanoma. Cochrane Database of Systematic Reviews.
CrossRef167
Hong Qin, Beatrisa Lerman, Ippei Sakamaki, Guowei Wei, Soungchul C Cha, Sheetal S Rao, Jianfei Qian, Yared Hailemichael, Roza Nurieva, Karen C Dwyer, Johannes Roth, Qing Yi, Willem W Overwijk, Larry W Kwak. . (2014) Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nature Medicine 20:6, 676-681.
CrossRef168
Sara Tomei, Ena Wang, Lucia Gemma Delogu, Francesco M Marincola, Davide Bedognetti. . (2014) Non-BRAF-targeted therapy, immunotherapy, and combination therapy for melanoma. Expert Opinion on Biological Therapy 14:5, 663-686.
CrossRef169
Steffen Rausch, Stephan Kruck, Arnulf Stenzl, Jens Bedke. . (2014) IMA901 for metastatic renal cell carcinoma in the context of new approaches to immunotherapy. Future Oncology 10:6, 937-948.
CrossRef170
Ronnie H. Fang, Che-Ming J. Hu, Brian T. Luk, Weiwei Gao, Jonathan A. Copp, Yiyin Tai, Derek E. O’Connor, Liangfang Zhang. . (2014) Cancer Cell Membrane-Coated Nanoparticles for Anticancer Vaccination and Drug Delivery. Nano Letters 14:4, 2181-2188.
CrossRef171
Theofilos Poutahidis, Markus Kleinewietfeld, Susan E. Erdman. . (2014) Gut Microbiota and the Paradox of Cancer Immunotherapy. Frontiers in Immunology 5.
CrossRef172
Christopher A. Barker, Michael A. Postow. . (2014) Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes. International Journal of Radiation Oncology*Biology*Physics 88:5, 986-997.
CrossRef173
Songwei Tan, Tetsuro Sasada, Anna Bershteyn, Kunyu Yang, Tetsuya Ioji, Zhiping Zhang. . (2014) Combinational delivery of lipid-enveloped polymeric nanoparticles carrying different peptides for anti-tumor immunotherapy. Nanomedicine 9:5, 635-647.
CrossRef174
Jérôme Galon, Gabriela Bindea, Bernhard Mlecnik, Helen Angell, Christine Lagorce, Ana Maria Todosi, Anne Berger, Franck Pagès. . (2014) Microenvironnement immunitaire et cancer. médecine/sciences 30:4, 439-444.
CrossRef175
Virgil Schijns, Eric Tartour, Jaroslav Michalek, Apostolos Stathopoulos, Neringa T. Dobrovolskienė, Marius M. Strioga. . (2014) Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines. Cytotherapy 16:4, 427-439.
CrossRef176
Haydn T. Kissick, Martin G. Sanda, Laura K. Dunn, Mohamed S. Arredouani, Thorbald van Hall. . (2014) Immunization with a Peptide Containing MHC Class I and II Epitopes Derived from the Tumor Antigen SIM2 Induces an Effective CD4 and CD8 T-Cell Response. PLoS ONE 9:4, e93231.
CrossRef177
Dilan Dissanayake, Kiichi Murakami, Michael D. Tran, Alisha R. Elford, Douglas G. Millar, Pamela S. Ohashi, Nathalie Labrecque. . (2014) Peptide-Pulsed Dendritic Cells Have Superior Ability to Induce Immune-Mediated Tissue Destruction Compared to Peptide with Adjuvant. PLoS ONE 9:3, e92380.
CrossRef178
Alexander MM Eggermont, Alan Spatz, Caroline Robert. . (2014) Cutaneous melanoma. The Lancet 383:9919, 816-827.
CrossRef179
M. Sebastian. . (2014) Impfung gegen Krebs. Forum 29:2, 121-124.
CrossRef180
Malte Mohme, Marian C. Neidert, Luca Regli, Michael Weller, Roland Martin. . (2014) Immunological challenges for peptide-based immunotherapy in glioblastoma. Cancer Treatment Reviews 40:2, 248-258.
CrossRef181
Howard Kaufman, Michael Wong, Gregory Daniels, David McDermott, Sandra Aung, James Lowder, Michael Morse. . (2014) The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2). Journal of Personalized Medicine 4:1, 52-64.
CrossRef182
Robert O. Dillman, Carol DePriest, Stephanie E. McClure. . (2014) High-Dose IL2 in Metastatic Melanoma: Better Survival in Patients Immunized with Antigens from Autologous Tumor Cell Lines. Cancer Biotherapy & Radiopharmaceuticals 29:2, 53-57.
CrossRef183
Laura M. Alwan, Kenneth Grossmann, Daniel Sageser, Joan Van Atta, Neeraj Agarwal, Jeffrey A. Gilreath. . (2014) Comparison of acute toxicity and mortality after two different dosing regimens of high-dose interleukin-2 for patients with metastatic melanoma. Targeted Oncology 9:1, 63-71.
CrossRef184
Denise Skrombolas, John G Frelinger. . (2014) Challenges and developing solutions for increasing the benefits of IL-2 treatment in tumor therapy. Expert Review of Clinical Immunology 10:2, 207-217.
CrossRef185
I Sakamaki, L W Kwak, S-c Cha, Q Yi, B Lerman, J Chen, S Surapaneni, S Bateman, H Qin. . (2014) Lenalidomide enhances the protective effect of a therapeutic vaccine and reverses immune suppression in mice bearing established lymphomas. Leukemia 28:2, 329-337.
CrossRef186
Geok Choo Sim, Natalia Martin-Orozco, Lei Jin, Yan Yang, Sheng Wu, Edwina Washington, Deborah Sanders, Carol Lacey, Yijun Wang, Luis Vence, Patrick Hwu, Laszlo Radvanyi. . (2014) IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients. Journal of Clinical Investigation 124:1, 99-110.
CrossRef187
Nayoung Lee, Steven R Barthel, Tobias Schatton. . (2014) Melanoma stem cells and metastasis: mimicking hematopoietic cell trafficking?. Laboratory Investigation 94:1, 13-30.
CrossRef188
S. Chandra, A.C. Pavlick, H.L. Kaufman. . 2014. Vaccines against Cancer. Reference Module in Biomedical Sciences.
CrossRef189
Vijaya B Joshi, Sean M Geary, Brett P Gross, Amaraporn Wongrakpanich, Lyse A Norian, Aliasger K Salem. . (2014) Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Review of Vaccines 13:1, 9-15.
CrossRef190
Sarah E. Church, Shawn M. Jensen, Paul A. Antony, Nicholas P. Restifo, Bernard A. Fox. . (2014) Tumor-specific CD4 + T cells maintain effector and memory tumor-specific CD8 + T cells. European Journal of Immunology 44:1, 69-79.
CrossRef191
Xiaoling Qian, Xian Wang, Hongchuan Jin. . (2014) Cell Transfer Therapy for Cancer: Past, Present, and Future. Journal of Immunology Research 2014, 1-9.
CrossRef192
Mehrdad Talebian Yazdi, Kevin R Keene, Pieter S Hiemstra, Sjoerd H van der Burg. . (2014) Recent progress in peptide vaccination in cancer with a focus on non-small-cell lung cancer. Expert Review of Vaccines 13:1, 87-116.
CrossRef193
Jeffrey Schlom, James W. Hodge, Claudia Palena, Kwong-Yok Tsang, Caroline Jochems, John W. Greiner, Benedetto Farsaci, Ravi A. Madan, Christopher R. Heery, James L. Gulley. . 2014. Therapeutic Cancer Vaccines. Advances in Cancer Research, 67-124.
CrossRef194
Atsushi Aruga, Nobuhiro Takeshita, Yoshihito Kotera, Ryuji Okuyama, Norimasa Matsushita, Takehiro Ohta, Kazuyoshi Takeda, Masakazu Yamamoto. . (2014) Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer. Journal of Translational Medicine 12:1, 61.
CrossRef195
A J Robert McGray, Robin Hallett, Dannie Bernard, Stephanie L Swift, Ziqiang Zhu, Florentina Teoderascu, Heather VanSeggelen, John A Hassell, Arthur A Hurwitz, Yonghong Wan, Jonathan L Bramson. . (2014) Immunotherapy-induced CD8+ T Cells Instigate Immune Suppression in the Tumor. Molecular Therapy 22:1, 206-218.
CrossRef196
Adi Diab, Robert R. Jenq, Gabrielle A. Rizzuto, Adam D. Cohen, Deonka W. Huggins, Taha Merghoub, Manuel E. Engelhorn, José A. Guevara-Patiño, David Suh, Vanessa M. Hubbard-Lucey, Adam A. Kochman, Suzie Chen, Hong Zhong, Jedd D. Wolchok, Marcel R. M. van den Brink, Alan N. Houghton, Miguel-Angel Perales, Hiroshi Shiku. . (2013) Enhanced Responses to Tumor Immunization Following Total Body Irradiation Are Time-Dependent. PLoS ONE 8:12, e82496.
CrossRef197
Muhammad Zulfiqar, Andrew David Thompson. . (2013) Current Applications of Molecular Genetic Technologies to the Diagnosis and Treatment of Cutaneous Melanocytic Neoplasms. Clinics in Laboratory Medicine 33:4, 881-890.
CrossRef198
Haydn Thomas Kissick, Martin George Sanda, Laura Kathleen Dunn, Mohamed Simo Arredouani. . (2013) Development of a peptide-based vaccine targeting TMPRSS2:ERG fusion-positive prostate cancer. Cancer Immunology, Immunotherapy 62:12, 1831-1840.
CrossRef199
Lingxiao Zhao, Min Zhang, Hua Cong. . (2013) Advances in the study of HLA-restricted epitope vaccines. Human vaccines & immunotherapeutics 9:12, 2566-2577.
CrossRef200
Francesco Sabbatino, Yangyang Wang, Xinhui Wang, Soldano Ferrone, Cristina R Ferrone. . (2013) Emerging BRAF inhibitors for melanoma. Expert Opinion on Emerging Drugs 18:4, 431-443.
CrossRef201
Lucio Tentori, Pedro Miguel Lacal, Grazia Graziani. . (2013) Challenging resistance mechanisms to therapies for metastatic melanoma. Trends in Pharmacological Sciences 34:12, 656-666.
CrossRef202
Brian Ahn, Ian Pollack, Hideho Okada. . (2013) Immune-Checkpoint Blockade and Active Immunotherapy for Glioma. Cancers 5:4, 1379-1412.
CrossRef203
Helen Gogas, Aristidis Polyzos, John Kirkwood. . (2013) Immunotherapy for advanced melanoma: Fulfilling the promise. Cancer Treatment Reviews 39:8, 879-885.
CrossRef204
Charles G. Drake, Evan J. Lipson, Julie R. Brahmer. . (2013) Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer. Nature Reviews Clinical Oncology 11:1, 24-37.
CrossRef205
Ryuji Okuyama, Atsushi Aruga, Takashi Hatori, Kazuyoshi Takeda, Masakazu Yamamoto. . (2013) Immunological responses to a multi-peptide vaccine targeting cancer-testis antigens and VEGFRs in advanced pancreatic cancer patients. OncoImmunology 2:11, e27010.
CrossRef206
Céline Robert-Tissot, Linh T Nguyen, Pamela S Ohashi, Daniel E Speiser. . (2013) Mobilizing and evaluating anticancer T cells: pitfalls and solutions. Expert Review of Vaccines 12:11, 1325-1340.
CrossRef207
Benedetto Farsaci, Peter Kim, James Hodge, Claudia Palena, James Gulley, Jeffrey Schlom. . 2013. Vaccine Therapy and Integration with Other Modalities. Targeted Therapies in Oncology, Second Edition, 341-366.
CrossRef208
Giorgio Parmiani, Carolina Cimminiello, Cristina Maccalli. . (2013) Increasing immunogenicity of cancer vaccines to improve their clinical outcome. Expert Review of Vaccines 12:10, 1111-1113.
CrossRef209
D. McDermott, J. Haanen, T.- T. Chen, P. Lorigan, S. O'Day, . . (2013) Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20). Annals of Oncology 24:10, 2694-2698.
CrossRef210
Madhury Ray, Jeffrey M. Farma, Cary Hsu. . (2013) Translational Research in Melanoma. Surgical Oncology Clinics of North America 22:4, 785-804.
CrossRef211
Karim Y Helmy, Shyam A Patel, George R Nahas, Pranela Rameshwar. . (2013) Cancer immunotherapy: accomplishments to date and future promise. Therapeutic Delivery 4:10, 1307-1320.
CrossRef212
Mark A. Suckow. . (2013) Cancer vaccines: Harnessing the potential of anti-tumor immunity. The Veterinary Journal 198:1, 28-33.
CrossRef213
Mario Mandalà, Christiane Voit. . (2013) Targeting BRAF in melanoma: Biological and clinical challenges. Critical Reviews in Oncology/Hematology 87:3, 239-255.
CrossRef214
John B.A.G. Haanen. . (2013) Immunotherapy of melanoma. European Journal of Cancer Supplements 11:2, 97-105.
CrossRef215
Gheath Alatrash, Haroon Jakher, Patricia D Stafford, Elizabeth A Mittendorf. . (2013) Cancer immunotherapies, their safety and toxicity. Expert Opinion on Drug Safety 12:5, 631-645.
CrossRef216
L. E. Mainetti, M. J. Rico, M. V. Fernández-Zenobi, H. A. Perroud, E. A. Roggero, V. R. Rozados, O. G. Scharovsky. . (2013) Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. Annals of Oncology 24:9, 2310-2316.
CrossRef217
Dragoslav Zikich, Jacob Schachter, Michal J. Besser. . (2013) Immunotherapy for the Management of Advanced Melanoma: The Next Steps. American Journal of Clinical Dermatology 14:4, 261-272.
CrossRef218
Krista M. Rubin. . (2013) Management of Primary Cutaneous and Metastatic Melanoma. Seminars in Oncology Nursing 29:3, 195-205.
CrossRef219
Anna Kozłowska, Jacek Mackiewicz, Andrzej Mackiewicz. . (2013) Therapeutic gene modified cell based cancer vaccines. Gene 525:2, 200-207.
CrossRef220
Jérôme Galon, Helen K. Angell, Davide Bedognetti, Francesco M. Marincola. . (2013) The Continuum of Cancer Immunosurveillance: Prognostic, Predictive, and Mechanistic Signatures. Immunity 39:1, 11-26.
CrossRef221
Geoffrey T Gibney, Jonathan S Zager. . (2013) Clinical development of dabrafenib in BRAF mutant melanoma and other malignancies. Expert Opinion on Drug Metabolism & Toxicology 9:7, 893-899.
CrossRef222
George E Peoples. . (2013) Rethinking cancer vaccines to avoid T-cell traps. Immunotherapy 5:7, 665-668.
CrossRef223
Elise P. Salerno, Sofia M. Shea, Walter C. Olson, Gina R. Petroni, Mark E. Smolkin, Chantel McSkimming, Kimberly A. Chianese-Bullock, Craig L. Slingluff. . (2013) Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund’s adjuvant, with or without peptide. Cancer Immunology, Immunotherapy 62:7, 1149-1159.
CrossRef224
Erik H. J. G. Aarntzen, Mangala Srinivas, Caius G. Radu, Cornelis J. A. Punt, Otto C. Boerman, Carl G. Figdor, Wim J. G. Oyen, I. Jolanda M. de Vries. . (2013) In vivo imaging of therapy-induced anti-cancer immune responses in humans. Cellular and Molecular Life Sciences 70:13, 2237-2257.
CrossRef225
Ena Wang, Davide Bedognetti, Francesco M. Marincola. . (2013) Prediction of Response to Anticancer Immunotherapy Using Gene Signatures. Journal of Clinical Oncology 31:19, 2369-2371.
CrossRef226
C Bryce Johnson, Mohamed L Salem, Shikhar Mehrotra, David J Cole, Mark P Rubinstein. . 2013. Tumours: Immunotherapy. eLS.
CrossRef227
Erin E. West, Hyun-Tak Jin, Ata-Ur Rasheed, Pablo Penaloza-MacMaster, Sang-Jun Ha, Wendy G. Tan, Ben Youngblood, Gordon J. Freeman, Kendall A. Smith, Rafi Ahmed. . (2013) PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. Journal of Clinical Investigation 123:6, 2604-2615.
CrossRef228
Marta Batus, Salman Waheed, Carl Ruby, Lindsay Petersen, Steven D. Bines, Howard L. Kaufman. . (2013) Optimal Management of Metastatic Melanoma: Current Strategies and Future Directions. American Journal of Clinical Dermatology 14:3, 179-194.
CrossRef229
Vincenzo Russo, Lorenzo Pilla, Francesca Lunghi, Roberto Crocchiolo, Raffaella Greco, Fabio Ciceri, Daniela Maggioni, Raffaella Fontana, Sylvain Mukenge, Licia Rivoltini, Gianluigi Rigamonti, Santo Raffaele Mercuri, Roberto Nicoletti, Alessandro Del Maschio, Luigi Gianolli, Ferruccio Fazio, Alfonso Marchianò, Annabella Di Florio, Michele Maio, Monica Salomoni, Corrado Gallo-Stampino, Matteo Del Fiacco, Antonio Lambiase, Pierre G. Coulie, Roberto Patuzzo, Giorgio Parmiani, Catia Traversari, Claudio Bordignon, Mario Santinami, Marco Bregni. . (2013) Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. International Journal of Cancer 132:11, 2557-2566.
CrossRef230
Robert O Dillman, Andrew N Cornforth, Gabriel Nistor. . (2013) Cancer stem cell antigen-based vaccines: the preferred strategy for active specific immunotherapy of metastatic melanoma?. Expert Opinion on Biological Therapy 13:5, 643-656.
CrossRef231
Yutaka Kawakami, Tomonori Yaguchi, Hidetoshi Sumimoto, Chie Kudo-Saito, Nobuo Tsukamoto, Tomoko Iwata-Kajihara, Shoko Nakamura, Hiroshi Nishio, Ryosuke Satomi, Asuka Kobayashi, Mayuri Tanaka, Jeong Hoon Park, Hajime Kamijuku, Takahiro Tsujikawa, Naoshi Kawamura. . (2013) Cancer-induced immunosuppressive cascades and their reversal by molecular-targeted therapy. Annals of the New York Academy of Sciences 1284:1, 80-86.
CrossRef232
Xiaoliang PANG, Kosuke TASHIRO, Rieko EGUCHI, Nobukazu KOMATSU, Tetsuro SASADA, Kyogo ITOH, Satoru KUHARA. . (2013) Haptoglobin Proved a Prognostic Biomarker in Peripheral Blood of Patients with Personalized Peptide Vaccinations for Advanced Castration-Resistant Prostate Cancer. Bioscience, Biotechnology, and Biochemistry 77:4, 766-770.
CrossRef233
Sebastian P Haen, Hans-Georg Rammensee. . (2013) The repertoire of human tumor-associated epitopes — identification and selection of antigens and their application in clinical trials. Current Opinion in Immunology 25:2, 277-283.
CrossRef234
Ramon Arens, Thorbald van Hall, Sjoerd H. van der Burg, Ferry Ossendorp, Cornelis J.M. Melief. . (2013) Prospects of combinatorial synthetic peptide vaccine-based immunotherapy against cancer. Seminars in Immunology 25:2, 182-190.
CrossRef235
Claudia Durán-Aniotz, Gabriela Segal, Lorena Salazar, Cristián Pereda, Cristián Falcón, Fabián Tempio, Raquel Aguilera, Rodrigo González, Claudio Pérez, Andrés Tittarelli, Diego Catalán, Bruno Nervi, Milton Larrondo, Flavio Salazar-Onfray, Mercedes N. López. . (2013) The immunological response and post-treatment survival of DC-vaccinated melanoma patients are associated with increased Th1/Th17 and reduced Th3 cytokine responses. Cancer Immunology, Immunotherapy 62:4, 761-772.
CrossRef236
T. Baba, H. Shiota, K. Kuroda, Y. Shigematsu, Y. Ichiki, H. Uramoto, T. Hanagiri, F. Tanaka. . (2013) Cancer/testis antigen expression as a predictor for epidermal growth factor receptor mutation and prognosis in lung adenocarcinoma. European Journal of Cardio-Thoracic Surgery 43:4, 759-764.
CrossRef237
Luis A. Sanchez-Perez, Bryan D. Choi, Gary E. Archer, Xiuyu Cui, Catherine Flores, Laura A. Johnson, Robert J. Schmittling, David Snyder, James E. Herndon, Darell D. Bigner, Duane A. Mitchell, John H. Sampson, Maciej S. Lesniak. . (2013) Myeloablative Temozolomide Enhances CD8+ T-Cell Responses to Vaccine and Is Required for Efficacy against Brain Tumors in Mice. PLoS ONE 8:3, e59082.
CrossRef238
Yared Hailemichael, Zhimin Dai, Nina Jaffarzad, Yang Ye, Miguel A Medina, Xue-Fei Huang, Stephanie M Dorta-Estremera, Nathaniel R Greeley, Giovanni Nitti, Weiyi Peng, Chengwen Liu, Yanyan Lou, Zhiqiang Wang, Wencai Ma, Brian Rabinovich, Kimberly S Schluns, Richard E Davis, Patrick Hwu, Willem W Overwijk. . (2013) Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion. Nature Medicine 19:4, 465-472.
CrossRef239
Tullia C. Bruno, Jena D. French, Kimberly R. Jordan, Oscar Ramirez, Trisha R. Sippel, Virginia F. Borges, Bryan R. Haugen, Martin D. McCarter, Allen Waziri, Jill E. Slansky. . (2013) Influence of human immune cells on cancer: studies at the University of Colorado. Immunologic Research 55:1-3, 22-33.
CrossRef240
Kavitha Yaddanapudi, Robert A. Mitchell, John W. Eaton. . (2013) Cancer vaccines. OncoImmunology 2:3, e23403.
CrossRef241
Scott A. Gerber, Elizabeth W. Sorensen, Abigail L. Sedlacek, Joanne Y. H. Lim, Denise Skrombolas, John G. Frelinger, Edith M. Lord. . (2013) Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology 138:3, 280-292.
CrossRef242
Tatiana Blanchard, Pramod K. Srivastava, Fei Duan. . (2013) Vaccines against advanced melanoma. Clinics in Dermatology 31:2, 179-190.
CrossRef243
Mingjun Wang, Bingnan Yin, Satoko Matsueda, Lijuan Deng, Ying Li, Wei Zhao, Jia Zou, Qingtian Li, Christopher Loo, Rong-Fu Wang, Helen Y. Wang, Silke Appel. . (2013) Identification of Special AT-Rich Sequence Binding Protein 1 as a Novel Tumor Antigen Recognized by CD8+ T Cells: Implication for Cancer Immunotherapy. PLoS ONE 8:2, e56730.
CrossRef244
F. Sandoval, M. Terme, M. Nizard, C. Badoual, M.-F. Bureau, L. Freyburger, O. Clement, E. Marcheteau, A. Gey, G. Fraisse, C. Bouguin, N. Merillon, E. Dransart, T. Tran, F. Quintin-Colonna, G. Autret, M. Thiebaud, M. Suleman, S. Riffault, T.-C. Wu, O. Launay, C. Danel, J. Taieb, J. Richardson, L. Zitvogel, W. H. Fridman, L. Johannes, E. Tartour. . (2013) Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors. Science Translational Medicine 5:172, 172ra20-172ra20.
CrossRef245
Heidi Braumüller, Thomas Wieder, Ellen Brenner, Sonja Aßmann, Matthias Hahn, Mohammed Alkhaled, Karin Schilbach, Frank Essmann, Manfred Kneilling, Christoph Griessinger, Felicia Ranta, Susanne Ullrich, Ralph Mocikat, Kilian Braungart, Tarun Mehra, Birgit Fehrenbacher, Julia Berdel, Heike Niessner, Friedegund Meier, Maries van den Broek, Hans-Ulrich Häring, Rupert Handgretinger, Leticia Quintanilla-Martinez, Falko Fend, Marina Pesic, Jürgen Bauer, Lars Zender, Martin Schaller, Klaus Schulze-Osthoff, Martin Röcken. . (2013) T-helper-1-cell cytokines drive cancer into senescence. Nature 494:7437, 361-365.
CrossRef246
Jianjun Gao, Chantale Bernatchez, Padmanee Sharma, Laszlo G. Radvanyi, Patrick Hwu. . (2013) Advances in the development of cancer immunotherapies. Trends in Immunology 34:2, 90-98.
CrossRef247
T. K. Eigentler, C. Garbe. . (2013) New landscape in the treatment of melanoma: a 2012 update. Oncologie 15:2, 71-77.
CrossRef248
Victor Barzey, Michael B. Atkins, Louis P. Garrison, Yumi Asukai, Srividya Kotapati, John R. Penrod. . (2013) Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis. Journal of Medical Economics 16:2, 202-212.
CrossRef249
Malgorzata Mackiewicz-Wysocka, Jakub Zolnierek, Piotr J Wysocki. . (2013) New therapeutic options in systemic treatment of advanced cutaneous melanoma. Expert Opinion on Investigational Drugs 22:2, 181-190.
CrossRef250
Gregory Lizée, Willem W. Overwijk, Laszlo Radvanyi, Jianjun Gao, Padmanee Sharma, Patrick Hwu. . (2013) Harnessing the Power of the Immune System to Target Cancer. Annual Review of Medicine 64:1, 71-90.
CrossRef251
J.A. Stockman. . (2013) gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. Yearbook of Pediatrics 2013, 31-33.
CrossRef252
Maria Ascierto, Michael O Idowu, Yingdong Zhao, Hanif Khalak, Kyle K Payne, Xiang-Yang Wang, Catherine I Dumur, Davide Bedognetti, Sara Tomei, Paolo A Ascierto, Anil Shanker, Harry D Bear, Ena Wang, Francesco M Marincola, Andrea De Maria, Masoud H Manjili. . (2013) Molecular signatures mostly associated with NK cells are predictive of relapse free survival in breast cancer patients. Journal of Translational Medicine 11:1, 145.
CrossRef253
Bishu Sapkota, Charles E. Hill, Brian P. Pollack. . (2013) Vemurafenib enhances MHC induction in BRAF V600E homozygous melanoma cells. OncoImmunology 2:1, e22890.
CrossRef254
Valerie R. Yanofsky, Hiroshi Mitsui, Diane Felsen, John A. Carucci. . (2013) Understanding Dendritic Cells and Their Role in Cutaneous Carcinoma and Cancer Immunotherapy. Clinical and Developmental Immunology 2013, 1-14.
CrossRef255
Davide Bedognetti, Ena Wang, Marimo Sato-Matsushita, Francesco M. Marincola, Maria Libera Ascierto. . 2013. Molecular Profiling of Immunotherapeutic Resistance. Cancer Immunotherapy, 373-394.
CrossRef256
Chunqing Guo, Masoud H. Manjili, John R. Subjeck, Devanand Sarkar, Paul B. Fisher, Xiang-Yang Wang. . 2013. Therapeutic Cancer Vaccines. Advances in Cancer Research, 421-475.
CrossRef257
Wei Liao, Jian-Xin Lin, Warren J. Leonard. . (2013) Interleukin-2 at the Crossroads of Effector Responses, Tolerance, and Immunotherapy. Immunity 38:1, 13-25.
CrossRef258
James M. Clark, Benjamin Kelley, Jill Titze, Henry Fung, John Maciejewski, Sunita Nathan, Elizabeth Rich, Sanjib Basu, Howard L. Kaufman. . (2013) Clinical and Safety Profile of High-Dose Interleukin-2 Treatment in Elderly Patients with Metastatic Melanoma and Renal Cell Carcinoma. Oncology 84:2, 123-126.
CrossRef259
Shingo Asahara, Kazuyoshi Takeda, Kenji Yamao, Hiroyuki Maguchi, Hiroki Yamaue. . (2013) Phase I/II clinical trial using HLA-A24-restricted peptide vaccine derived from KIF20A for patients with advanced pancreatic cancer. Journal of Translational Medicine 11:1, 291.
CrossRef260
Kowichi Jimbow, Yasue Ishii-Osai, Shosuke Ito, Yasuaki Tamura, Akira Ito, Akihiro Yoneta, Takafumi Kamiya, Toshiharu Yamashita, Hiroyuki Honda, Kazumasa Wakamatsu, Katsutoshi Murase, Satoshi Nohara, Eiichi Nakayama, Takeo Hasegawa, Itsuo Yamamoto, Takeshi Kobayashi. . (2013) Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles. Journal of Skin Cancer 2013, 1-12.
CrossRef261
Steffen Walter, Toni Weinschenk, Carsten Reinhardt, Harpreet Singh-Jasuja. . (2013) Single-dose cyclophosphamide synergizes with immune responses to the renal cell cancer vaccine IMA901. OncoImmunology 2:1, e22246.
CrossRef262
Soo Jung Lee, Yee Soo Chae. . (2013) New Systemic Treatment for Malignant Melanoma. Korean Journal of Medicine 85:4, 357.
CrossRef263
Freda K. Stevenson, Gianfranco di Genova, Christian H. Ottensmeier, Natalia Savelyeva. . 2013. Genetic Vaccines against Cancer. Cancer Immunotherapy, 223-239.
CrossRef264
Mathilde Bobinet, Virginie Vignard, Anne Rogel, Amir Khammari, Brigitte Dreno, Francois Lang, Nathalie Labarriere, Sylvie Le Gall. . (2012) MELOE-1 Antigen Contains Multiple HLA Class II T Cell Epitopes Recognized by Th1 CD4+ T Cells from Melanoma Patients. PLoS ONE 7:12, e51716.
CrossRef265
Laura Finn, Svetomir N Markovic, Richard W Joseph. . (2012) Therapy for metastatic melanoma: the past, present, and future. BMC Medicine 10:1.
CrossRef266
Erika Vacchelli, Isabelle Martins, Alexander Eggermont, Wolf Hervé Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi. . (2012) Trial watch. OncoImmunology 1:9, 1557-1576.
CrossRef267
Slava Stamova, Stefanie Koristka, Juliane Keil, Claudia Arndt, Anja Feldmann, Irene Michalk, Holger Bartsch, Claudia C. Bippes, Marc Schmitz, Marc Cartellieri, Michael Bachmann. . (2012) Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs. Antibodies 1:3, 172-198.
CrossRef268
Kousuke Tanaka, Satoru Ishikawa, Yasunori Matsui, Takashi Kawanishi, Makoto Tamesada, Nanae Harashima, Mamoru Harada. . (2012) Combining a peptide vaccine with oral ingestion of Lentinula edodes mycelia extract enhances anti-tumor activity in B16 melanoma-bearing mice. Cancer Immunology, Immunotherapy 61:11, 2143-2152.
CrossRef269
Lindsey Chudley, Katy McCann, Ann Mander, Torunn Tjelle, Juan Campos-Perez, Rosemary Godeseth, Antonia Creak, James Dobbyn, Bernadette Johnson, Paul Bass, Catherine Heath, Paul Kerr, Iacob Mathiesen, David Dearnaley, Freda Stevenson, Christian Ottensmeier. . (2012) DNA fusion-gene vaccination in patients with prostate cancer induces high-frequency CD8+ T-cell responses and increases PSA doubling time. Cancer Immunology, Immunotherapy 61:11, 2161-2170.
CrossRef270
Diwakar Davar, John Munn Kirkwood. . (2012) New therapies in the treatment of melanoma. Expert Opinion on Investigational Drugs 21:11, 1643-1659.
CrossRef271
Jürgen C. Becker, Mads H. Andersen, Valeska Hofmeister-Müller, Marion Wobser, Lidia Frey, Christiane Sandig, Steffen Walter, Harpreet Singh-Jasuja, Eckhart Kämpgen, Andreas Opitz, Marc Zapatka, Eva-B. Bröcker, Per thor Straten, David Schrama, Selma Ugurel. . (2012) Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma. Cancer Immunology, Immunotherapy 61:11, 2091-2103.
CrossRef272
Theresa L. Whiteside, Patrick Schuler, Bastian Schilling. . (2012) Induced and natural regulatory T cells in human cancer. Expert Opinion on Biological Therapy 12:10, 1383-1397.
CrossRef273
Walter J Urba, Brendan D Curti. . (2012) Metastatic melanoma can be cured: advances in immunotherapy and targeted approaches. Clinical Investigation 2:10, 957-959.
CrossRef274
Ronnie Shapira-Frommer, Jacob Schachter. . (2012) Adoptive Immunotherapy of Advanced Melanoma. Current Treatment Options in Oncology 13:3, 340-353.
CrossRef275
S.P. Haen, P. Brossart, H.-G. Rammensee. . (2012) Tumorvakzinierung. Der Onkologe 18:9, 795-800.
CrossRef276
Brendan D. Curti, Walter J. Urba. . (2012) Integrating New Therapies in the Treatment of Advanced Melanoma. Current Treatment Options in Oncology 13:3, 327-339.
CrossRef277
C. G. Drake. . (2012) Combination immunotherapy approaches. Annals of Oncology 23:suppl 8, viii41-viii46.
CrossRef278
J. Weng, S. Rawal, F. Chu, H. J. Park, R. Sharma, D. A. Delgado, L. Fayad, M. Fanale, J. Romaguera, A. Luong, L. W. Kwak, S. S. Neelapu. . (2012) TCL1: a shared tumor-associated antigen for immunotherapy against B-cell lymphomas. Blood 120:8, 1613-1623.
CrossRef279
Hamdy A.A. Aly. . (2012) Cancer therapy and vaccination. Journal of Immunological Methods 382:1-2, 1-23.
CrossRef280
Theresa L. Whiteside. . (2012) What are regulatory T cells (Treg) regulating in cancer and why?. Seminars in Cancer Biology 22:4, 327-334.
CrossRef281
Steffen Walter, Toni Weinschenk, Arnulf Stenzl, Romuald Zdrojowy, Anna Pluzanska, Cezary Szczylik, Michael Staehler, Wolfram Brugger, Pierre-Yves Dietrich, Regina Mendrzyk, Norbert Hilf, Oliver Schoor, Jens Fritsche, Andrea Mahr, Dominik Maurer, Verona Vass, Claudia Trautwein, Peter Lewandrowski, Christian Flohr, Heike Pohla, Janusz J Stanczak, Vincenzo Bronte, Susanna Mandruzzato, Tilo Biedermann, Graham Pawelec, Evelyna Derhovanessian, Hisakazu Yamagishi, Tsuneharu Miki, Fumiya Hongo, Natsuki Takaha, Kosei Hirakawa, Hiroaki Tanaka, Stefan Stevanovic, Jürgen Frisch, Andrea Mayer-Mokler, Alexandra Kirner, Hans-Georg Rammensee, Carsten Reinhardt, Harpreet Singh-Jasuja. . (2012) Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nature Medicine 18:8, 1254-1261.
CrossRef282
Lukas Baitsch, Silvia A. Fuertes-Marraco, Amandine Legat, Christiane Meyer, Daniel E. Speiser. . (2012) The three main stumbling blocks for anticancer T cells. Trends in Immunology 33:7, 364-372.
CrossRef283
An M. T. Van Nuffel, Daphné Benteyn, Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Bart Neyns, Kris Thielemans, Aude Bonehill. . (2012) Intravenous and intradermal TriMix-dendritic cell therapy results in a broad T-cell response and durable tumor response in a chemorefractory stage IV-M1c melanoma patient. Cancer Immunology, Immunotherapy 61:7, 1033-1043.
CrossRef284
Nobukazu Komatsu, Satoko Matsueda, Kousuke Tashiro, Tetsuya Ioji, Shigeki Shichijo, Masanori Noguchi, Akira Yamada, Atsushi Doi, Shigetaka Suekane, Fukuko Moriya, Kei Matsuoka, Satoru Kuhara, Kyogo Itoh, Tetsuro Sasada. . (2012) Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination. Cancer 118:12, 3208-3221.
CrossRef285
S. K. Seung, B. D. Curti, M. Crittenden, E. Walker, T. Coffey, J. C. Siebert, W. Miller, R. Payne, L. Glenn, A. Bageac, W. J. Urba. . (2012) Phase 1 Study of Stereotactic Body Radiotherapy and Interleukin-2--Tumor and Immunological Responses. Science Translational Medicine 4:137, 137ra74-137ra74.
CrossRef286
Mark J. Adler, Dimiter S. Dimitrov. . (2012) Therapeutic Antibodies Against Cancer. Hematology/Oncology Clinics of North America 26:3, 447-481.
CrossRef287
Andrzej Mackiewicz, Jacek Mackiewicz, Piotr J. Wysocki, Maciej Wiznerowicz, Malgorzata Kapcinska, Maria Laciak, Stefan Rose-John, Dariusz Izycki, Tomasz Burzykowski, Aldona Karczewska-Dzionk. . (2012) Long-term survival of high-risk melanoma patients immunized with a Hyper-IL-6-modified allogeneic whole-cell vaccine after complete resection. Expert Opinion on Investigational Drugs 21:6, 773-783.
CrossRef288
Mark Sanford. . (2012) Ipilimumab. BioDrugs 26:3, 185-193.
CrossRef289
Diane F Hale, G Travis Clifton, Alan K Sears, Timothy J Vreeland, Nathan Shumway, George E Peoples, Elizabeth A Mittendorf. . (2012) Cancer vaccines: should we be targeting patients with less aggressive disease?. Expert Review of Vaccines 11:6, 721-731.
CrossRef290
Howard L. Kaufman. . (2012) Vaccines for Melanoma and Renal Cell Carcinoma. Seminars in Oncology 39:3, 263-275.
CrossRef291
Wai M. Liu, Angus G. Dalgleish. . (2012) The Potential Beneficial Effects of Drugs on the Immune Response to Vaccination. Seminars in Oncology 39:3, 340-347.
CrossRef292
Ena Wang, Sara Tomei, Francesco M. Marincola. . (2012) Reflections upon human cancer immune responsiveness to T cell-based therapy. Cancer Immunology, Immunotherapy 61:6, 761-770.
CrossRef293
Benjamin Weide, Henning Zelba, Evelyna Derhovanessian, Annette Pflugfelder, Thomas K. Eigentler, Anna Maria Di Giacomo, Michele Maio, Erik H.J.G. Aarntzen, I. Jolanda M. de Vries, Antje Sucker, Dirk Schadendorf, Petra Büttner, Claus Garbe, Graham Pawelec. . (2012) Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. Journal of Clinical Oncology 30:15, 1835-1841.
CrossRef294
Vera P. Krymskaya. . (2012) Treatment Option(s) for Pulmonary Lymphangioleiomyomatosis: Progress and Current Challenges. American Journal of Respiratory Cell and Molecular Biology 46:5, 563-565.
CrossRef295
Raymund L. Yong, Russell R. Lonser. . (2012) Immunotherapy Trials for Glioblastoma Multiforme: Promise and Pitfalls. World Neurosurgery 77:5-6, 636-638.
CrossRef296
LeeAnn T. Blalock, Jennifer Landsberg, Michelle Messmer, Jian Shi, Angela D. Pardee, Ronald Haskell, Lazar Vujanovic, John M. Kirkwood, Lisa H. Butterfield. . (2012) Human dendritic cells adenovirally-engineered to express three defined tumor antigens promote broad adaptive and innate immunity. OncoImmunology 1:3, 287-357.
CrossRef297
Masafumi Shimoda, Yoshito Tomimaru, Kevin P. Charpentier, Howard Safran, Rolf I. Carlson, Jack Wands. . (2012) Tumor progression-related transmembrane protein aspartate-β-hydroxylase is a target for immunotherapy of hepatocellular carcinoma. Journal of Hepatology 56:5, 1129-1135.
CrossRef298
Lorenzo Galluzzi, Erika Vacchelli, Alexander Eggermont, Wolf Herve´ Fridman, Jerome Galon, Catherine Sautès-Fridman, Eric Tartour, Laurence Zitvogel, Guido Kroemer. . (2012) Trial Watch. OncoImmunology 1:3, 306-315.
CrossRef299
J. Schlom. . (2012) Therapeutic Cancer Vaccines: Current Status and Moving Forward. JNCI Journal of the National Cancer Institute 104:8, 599-613.
CrossRef300
Francesca Avogadri, Jedd D Wolchok. . (2012) Selecting antigens for cancer vaccines. Nature Biotechnology 30:4, 328-329.
CrossRef301
Michele Guida, Salvatore Pisconti, Giuseppe Colucci. . (2012) Metastatic melanoma: the new era of targeted therapy. Expert Opinion on Therapeutic Targets 16:sup2, S61-S70.
CrossRef302
Satish Kumar, Malcolm Mason. . (2012) Principles of cancer treatment by immunotherapy. Surgery (Oxford) 30:4, 198-202.
CrossRef303
S. A. Rosenberg. . (2012) Raising the Bar: The Curative Potential of Human Cancer Immunotherapy. Science Translational Medicine 4:127, 127ps8-127ps8.
CrossRef304
An M.T. Van Nuffel, Sandra Tuyaerts, Daphné Benteyn, Sofie Wilgenhof, Jurgen Corthals, Carlo Heirman, Bart Neyns, Kris Thielemans, Aude Bonehill. . (2012) Epitope and HLA-type independent monitoring of antigen-specific T-cells after treatment with dendritic cells presenting full-length tumor antigens. Journal of Immunological Methods 377:1-2, 23-36.
CrossRef305
Vasiliki A. Nikolaou, Alexander J. Stratigos, Keith T. Flaherty, Hensin Tsao. . (2012) Melanoma: New Insights and New Therapies. Journal of Investigative Dermatology 132:3, 854-863.
CrossRef306
Christopher R. Zito, Harriet M. Kluger. . (2012) Immunotherapy for metastatic melanoma. Journal of Cellular Biochemistry 113:3, 725-734.
CrossRef307
Jeffrey Schlom. . (2012) Recent Advances in Therapeutic Cancer Vaccines. Cancer Biotherapy & Radiopharmaceuticals 27:1, 2-5.
CrossRef308
Takashi Mori, Satoshi Nishizawa, Yoshihiko Hirohashi, Toshihiko Torigoe, Yasuaki Tamura, Akari Takahashi, Vitaly Kochin, Reona Fujii, Toru Kondo, Mark I. Greene, Isao Hara, Noriyuki Sato. . (2012) Efficiency of G2/M-related tumor-associated antigen-targeting cancer immunotherapy depends on antigen expression in the cancer stem-like population. Experimental and Molecular Pathology 92:1, 27-32.
CrossRef309
Anatoli M. Malyguine, Susan L. Strobl, Michael R. Shurin. . (2012) Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunology, Immunotherapy 61:2, 239-247.
CrossRef310
Katie E Lacy, Sophia N Karagiannis, Frank O Nestle. . (2012) Immunotherapy for melanoma. Expert Review of Dermatology 7:1, 51-68.
CrossRef311
Koji Kono, Hisae Iinuma, Yasunori Akutsu, Hiroaki Tanaka, Naoko Hayashi, Yasuto Uchikado, Tsuyoshi Noguchi, Hideki Fujii, Kota Okinaka, Ryoji Fukushima, Hisahiro Matsubara, Masaichi Ohira, Hideo Baba, Shoji Natsugoe, Seigou Kitano, Kazuyoshi Takeda, Koji Yoshida, Takuya Tsunoda, Yusuke Nakamura. . (2012) Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens. Journal of Translational Medicine 10:1, 141.
CrossRef312
Sebastian Bauer, Heinz Schmidberger, Uwe Trefzer. . (2012) Individualisierte Tumortherapie und Status quo beim Melanom. Onkologie 35:s2, 2-6.
CrossRef313
T.J. Eberlein. . (2012) gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma. Yearbook of Surgery 2012, 350-352.
CrossRef314
Brian P. Pollack. . (2012) EGFR inhibitors, MHC expression and immune responses : Can EGFR inhibitors be used as immune response modifiers?. OncoImmunology 1:1, 71-74.
CrossRef315
Esther D. Quakkelaar, Cornelis J.M. Melief. . 2012. Experience with Synthetic Vaccines for Cancer and Persistent Virus Infections in Nonhuman Primates and Patients. Synthetic Vaccines, 77-106.
CrossRef316
Bedognetti Davide, Wang Ena, Sertoli Mario Roberto, Marincola Francesco M. . 2012. Melanoma & biomarkers of immunoresponsiveness. Emerging Therapeutics for Melanoma, 120-152.
CrossRef317
Ruggero Ridolfi, Laura Ridolfi, Stefania Vittoria Luisa Nicoletti, Massimo Guidoboni. . 2012. Melanoma vaccines in development. Emerging Therapeutics for Melanoma, 104-119.
CrossRef318
Francesco M Marincola, Paolo Ascierto, John M Kirkwood. . 2012. Emerging therapeutics for melanoma. Emerging Therapeutics for Melanoma, 2-5.
CrossRef319
Richard Wu, Marie-Andrée Forget, Jessica Chacon, Chantale Bernatchez, Cara Haymaker, Jie Qing Chen, Patrick Hwu, Laszlo G. Radvanyi. . (2012) Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. The Cancer Journal 18:2, 160-175.
CrossRef320
Grazia Graziani, Lucio Tentori, Pierluigi Navarra. . (2012) Ipilimumab: A novel immunostimulatory monoclonal antibody for the treatment of cancer. Pharmacological Research 65:1, 9-22.
CrossRef321
Helen Y. Wang, Rong-Fu Wang. . 2012. Enhancing Cancer Immunotherapy by Intracellular Delivery of Cell-Penetrating Peptides and Stimulation of Pattern-Recognition Receptor Signaling. Synthetic Vaccines, 151-176.
CrossRef322
Ira Mellman, George Coukos, Glenn Dranoff. . (2011) Cancer immunotherapy comes of age. Nature 480:7378, 480-489.
CrossRef323
Suzanne L. Topalian, George J. Weiner, Drew M. Pardoll. . (2011) Cancer Immunotherapy Comes of Age. Journal of Clinical Oncology 29:36, 4828-4836.
CrossRef324
Benjamin Scheier, Rodabe Amaria, Karl Lewis, Rene Gonzalez. . (2011) Novel therapies in melanoma. Immunotherapy 3:12, 1461-1469.
CrossRef325
Sylvia Lee, Kim Margolin. . (2011) Cytokines in Cancer Immunotherapy. Cancers 3:4, 3856-3893.
CrossRef326
E. H. J. G. Aarntzen, M. Srinivas, J. H. W. De Wilt, J. F. M. Jacobs, W. J. Lesterhuis, A. D. Windhorst, E. G. Troost, J. J. Bonenkamp, M. M. van Rossum, W. A. M. Blokx, R. D. Mus, O. C. Boerman, C. J. A. Punt, C. G. Figdor, W. J. G. Oyen, I. J. M. de Vries. . (2011) Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. Proceedings of the National Academy of Sciences 108:45, 18396-18399.
CrossRef327
Stephen J Clarke. . 2011. Successes, challenges and future directions. Advances in Personalized Cancer Management, 84-95.
CrossRef328
Padmanee Sharma, Klaus Wagner, Jedd D. Wolchok, James P. Allison. . (2011) Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nature Reviews Cancer 11:11, 805-812.
CrossRef329
Éric Tartour, Federico Sandoval, Jean-Yves Bonnefoy, Wolf H. Fridman. . (2011) Immunothérapie des cancers. médecine/sciences 27:10, 833-841.
CrossRef330
Michael Postow, Margaret K. Callahan, Jedd D. Wolchok. . (2011) Beyond Cancer Vaccines. The Cancer Journal 17:5, 372-378.
CrossRef331
Giorgio Parmiani, Lorenzo Pilla, Cristina Maccalli, Vincenzo Russo. . (2011) Autologous Versus Allogeneic Cell-Based Vaccines?. The Cancer Journal 17:5, 331-336.
CrossRef332
Craig L. Slingluff. . (2011) The Present and Future of Peptide Vaccines for Cancer. The Cancer Journal 17:5, 343-350.
CrossRef333
Sarah E. Church, Shawn M. Jensen, Christopher G. Twitty, Keith Bahjat, Hong-Ming Hu, Walter J. Urba, Bernard A. Fox. . (2011) Multiple Vaccinations. The Cancer Journal 17:5, 379-396.
CrossRef334
Alexander M.M. Eggermont. . (2011) Therapeutic Cancer Vaccine Development. The Cancer Journal 17:5, 276.
CrossRef335
James C. Yang. . (2011) Melanoma Vaccines. The Cancer Journal 17:5, 277-282.
CrossRef336
Teofila Seremet, Francis Brasseur, Pierre G. Coulie. . (2011) Tumor-Specific Antigens and Immunologic Adjuvants in Cancer Immunotherapy. The Cancer Journal 17:5, 325-330.
CrossRef337
Gerold Schuler. . (2011) Dendritic Cells. The Cancer Journal 17:5, 337-342.
CrossRef338
(2011) gp100 Peptide Vaccine in Melanoma. New England Journal of Medicine 365:8, 771-771.
Free Full Text339
Shuji Ogino, Jérôme Galon, Charles S. Fuchs, Glenn Dranoff. . (2011) Cancer immunology—analysis of host and tumor factors for personalized medicine. Nature Reviews Clinical Oncology 8:12, 711-719.
CrossRef340
W. Joost Lesterhuis, John B. A. G. Haanen, Cornelis J. A. Punt. . (2011) Cancer immunotherapy – revisited. Nature Reviews Drug Discovery 10:8, 591-600.
CrossRef341
Vernon K. Sondak, Lawrence E. Flaherty. . (2011) Targeted therapies: Improved outcomes for patients with metastatic melanoma. Nature Reviews Clinical Oncology 8:9, 513-515.
CrossRef342
Nagendra Natarajan, Sucheta Telang, Donald Miller, Jason Chesney. . (2011) Novel Immunotherapeutic Agents and Small Molecule Antagonists of Signalling Kinases for the Treatment of Metastatic Melanoma. Drugs 71:10, 1233-1250.
CrossRef343
Maria Ascierto, Valeria De Giorgi, Qiuzhen Liu, Davide Bedognetti, Tara L Spivey, Daniela Murtas, Lorenzo Uccellini, Ben D Ayotte, David F Stroncek, Lotfi Chouchane, Masoud H Manjili, Ena Wang, Francesco M Marincola. . (2011) An immunologic portrait of cancer. Journal of Translational Medicine 9:1, 146.
CrossRef
- Letters
- Metrics
Social Media statistics are not yet available.